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Constructing gene expression based prognostic models to predict recurrence and lymph node 
metastasis in colon cancer 
Ramakanth Reddy Mettu 
The main goal of this study is to identify molecular signatures to predict lymph node metastases and 
recurrence in colon cancer patients. Recent advances in microarray technology facilitated building of 
accurate molecular classifiers, and in depth understanding of disease mechanisms. 
Lymph node metastasis cannot be accurately estimated by morphological assessment. Molecular markers 
have the potential to improve prognostic accuracy. The first part of our study presents a novel technique 
to identify molecular markers for predicting stage of the disease based on microarray gene expression 
data. In the first step, random forests were used for variable selection and a 14-gene signature was 
identified. In the second step, the genes without differential expression in lymph node negative versus 
positive tumors were removed from the 14-gene signature, leading to the identification of a 9-gene 
signature. The lymph node status prediction accuracy of the 9-gene signature on an independent colon 
cancer dataset (n=17) was 82.3%. Area under curve (AUC) obtained from the time-dependent ROC 
curves using the 9-gene signature was 0.85 and 0.86 for relapse-free survival and overall survival, 
respectively. The 9-gene signature significantly stratified patients into low-risk and high-risk groups (log-
rank tests, p<0.05, n=73), with distinct relapse-free survival and overall survival. Based on the results, it 
could be concluded that the 9-gene signature could be used to identify lymph node metastases in patients. 
We further studied the 9-gene signature using correlation analysis on CGH and RNA expression datasets. 
It was found that the gene ITGB1 in the 9-gene signature exhibited strong relationship of DNA copy 
number and gene expression. Furthermore, genome-wide correlation analysis was done on CGH and 
RNA data, and three or more consecutive genes with significant correlation of DNA copy number and 
RNA expression were identified. These results might be helpful in identifying the regulators of gene 
expression. 
The second part of the study was focused on identifying molecular signatures for patients at high-risk for 
recurrence who would benefit from adjuvant chemotherapy. The training set (n=36) consisted of patients 
who remained disease-free for 5 years and patients who experienced recurrence within 5 years. The 
remaining patients formed the testing set (n=37). A combinatorial scheme was developed to identify gene 
signatures predicting colon cancer recurrence. In the first step, preprocessing was done to discard 
undifferentiated genes and missing values were replaced with k=30 and k=20 using the k-nearest 
neighbors algorithm. Variable selection using the random forests algorithm was applied to obtain gene 
subsets. In the second step, InfoGain feature selection technique was used to drop lower ranked genes 
from the gene subsets based on their association with disease outcome. A 3-gene and a 5-gene signature 
were identified by this technique based on different missing value replacement methods. Both of the 
recurrence gene signatures stratified patients into low-risk and high-risk groups (log-rank tests, p<0.05, 
n=73), with distinct relapse-free survival and overall survival. A recurrence prediction model was built 
using LWL classifier based on the 3-gene signature with an accuracy of 91.7% on the training set (n=36). 
Another recurrence prediction model was built using the random tree classifier based on the 5-gene 
signature with an accuracy of 83.3% on the training set (n=36). The prospective predictions obtained on 
the testing set using these models will be verified when the follow-up information becomes available in 
the future. The recurrence prediction accuracies of these gene signatures on independent colon cancer 
datasets were in the range 72.4% to 88.9%. These prognostic models might be helpful to clinicians in 
selecting more appropriate treatments for patients who are at high-risk of developing recurrence. When 
compared over multiple datasets, the 3-gene signature had improved prediction accuracy over the 5-gene 
signature. The identified lymph node and recurrence gene signatures were validated on rectal cancer data. 
Time-dependent ROC and Kaplan-Meier analysis were done producing significant results. These results 
support the fact that the developed prognostic models could be used to identify patients at high-risk of 
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Colon cancer is the third most common cause of cancer in Europe and the United States, with ~300,000 
new cases and 200,000 deaths each year. It is the second most common site (after lung) to cause cancer 
death1. The primary treatment for colon cancer is the surgical removal of a part of colon or the entire 
colon. Chemotherapy after surgery can prolong the survival in patients if the cancer has spread to nearby 
lymph nodes. Prognosis is the estimation of disease outcome i.e., the chance that a patient will recover or 
have a recurrence (return of the cancer)2
 In the recent years, advances in genetic technologies such as cDNA microarrays allowed for 
measuring the expression of tens of thousands of genes simultaneously. The research carried out in this 
area over the past few years has demonstrated that the gene expression data could be used to solve a 
variety of problems like tumor classification and prediction of treatment response. Machine learning and 
statistical techniques have been successfully applied on the gene expression datasets to identify 
biomarkers, predict recurrence or disease outcome, distinguish between tumor and normal tissue samples, 
build prognostic predictors and predict treatment response (1). Currently, two gene expression based tests 
are being used in clinical trials for breast cancer prognosis. The MammaPrint
. The most important factors that affect the colon cancer 
prognosis are the histology, location, and stage of the disease (the extent to which the cancer has spread). 
Doctors cannot be absolutely certain about the outcome for a particular patient based on the traditional 
morphological assessment. 
3









low or high-risk of recurrence. The Oncotype DX4
Staging is an important prognostic factor in determining treatment options. Earlier stages of colon 
cancer (stage I and stage II) have good chances of prognosis compared to later stages (stage III and stage 
IV)
 test determines the likelihood of recurrence. There are 
no gene tests available for colon cancer prognosis at present. 
5
 The first part of our study aims at building prognostic models based on the microarray gene 
expression data to predict lymph node metastasis (stage). The colon cancer microarray data used in this 
study contained 73 tumor samples of which 33 samples were stage II tumors and 40 samples were stage 
III tumors (2). The data was preprocessed by applying t-tests
. When a patient is diagnosed with cancer, various clinical parameters are used to assess the risk of 
metastasis and death in the patient. However, despite numerous advances in this area, the ability to 
accurately estimate the risk of morbidity is limited. Tumors that appear indistinguishable under the 
microscope can have different outcome and different treatment response. This could be due to the 
differences in the genetic profiles of the tumors. With the advent of cDNA microarray technology, it is 
possible to measure the expression levels of thousands of genes simultaneously and the differences 
between tumors at the molecular level can be detected. Thus molecular markers identified based on the 
cDNA microarray expression data have the potential to improve prognostic accuracy significantly. The 
disease prognosis can be assessed preoperatively through a tissue obtained from a colonoscopic biopsy 
specimen or post operatively from a resected tumor. 
6




 on genes that had missing values in more 
than 5 samples. Genes passing the t-tests along with all genes having less than 5 missing values, a total of 
10,220 genes, were included for further analysis. This data was randomly split in 2:1 ratio as training and 
testing sets. The training set contained 10,220 genes and 50 samples. A 9-gene lymph node status 
signature was identified by a novel technique from the training set. In this technique, firstly, variable 





tests7 were applied on the 14-gene signature to discard the genes without differential expression in lymph 
node negative versus positive tumor samples. This resulted in a 9-gene signature. The performance of the 
9-gene signature was evaluated by cross validation on independent colon cancer data sets. A number of 
machine learning algorithms were applied on validation datasets, but none of the algorithms gave 
consistent results on all the validation datasets. So, classifiers with highest prediction accuracy on each 
dataset were chosen. J48, Naïve Bayes, Decision stump and Threshold selector were the classifiers used 
for validation of independent datasets. The 9-gene signature was used to predict lymph node status on 
Koinuma et al data (n=17), recurrence on Barrier et al data (PMID 16091735) (n=12), Barrier et al data 
(PMID 16966692) (n=50), Barrier et al data (PMID 17043639) (n=24), and drug response on NCI-608
 Recurrence is the reappearance of a tumor or the return of symptoms after treating for cancer. 
Adjuvant chemotherapy is the main treatment given to Duke’s stage C patients (node-positive disease). In 
Duke’s stage B patients (node negative disease) no adjuvant chemotherapy is used after surgery, although 
25% to 40% of patients usually develop recurrence (5). It is not clear whether adjuvant chemotherapy 
should be given to Duke’s stage B patients as not all the patients would benefit from it. Partitioning 
patients into low-risk and high-risk groups would allow in “more aggressive” and accurate treatment 
strategies for the patients at high-risk of recurrence, and spare the patients in the low-risk group from the 
“aggressive treatment” through which they are unlikely to be benefited. The TNM (tumor-node-
metastasis) staging system is the main tool for identifying prognostic differences (6), but this system is 
 
data (n=34). Further time-dependent ROC analysis was done to get an estimate of the discriminatory 
power of the identified biomarker. Kaplan-Meier analysis generated significant patient stratification into 
subgroups (p<0.05, n=73, log-rank tests) with distinct relapse-free survival and overall survival, 
respectively. Correlation analysis was done on CGH and RNA data to identify cDNA copy numbers 
correlated with gene expression data. The locations of these genes might be important in identifying the 
regulators of the gene expression (4). 







not sufficient for predicting recurrence in Duke’s stage B patients (7). Thus, there are limitations for 
predicting recurrence by using traditional methods. So there is a need to identify patients at high-risk of 
recurrence who would develop relapse in the Duke’s B group.  
 
The second part of our study specifically aims at identifying patients at high-risk of recurrence by 
building prognostic models for stage II (Duke’s stage B) and stage III (Duke’s stage C) colon cancer 
patients. This is achieved by a novel combinatorial feature selection scheme. The missing values in the 
gene expression data were replaced by k-nearest neighbors algorithm with k=30 and k=20, separately. In 
the first step, variable selection using random forests is done on the training set which comprised of 36 
patients. This step obtained two recurrence gene signatures based on different missing value replacement 
methods. In the second step, InfoGain feature selection technique (12) was applied to further reduce the 
dimensionality, and this led to the identification of the 3-gene signature and the 5-gene signature on 
datasets generated with different missing value replacements. The performances of both gene signatures 
were evaluated by cross validation on independent colon cancer data sets. A number of machine learning 
algorithms have been tested for the validation of these signatures, but no particular scheme gave 
consistent results on all the datasets. So, classifiers with highest prediction accuracy on each dataset were 
chosen. LWL and Random Tree were the classifiers chosen to build prediction models using 3-gene and 
5-gene signatures, respectively. KStar, AD Tree, IB1 and Threshold selector were the classifiers used for 
validation of independent datasets. The 3-gene and 5-gene recurrence signatures were used to predict 
lymph node status on Koinuma et al data (n=17), recurrence on Barrier et al data (PMID 16091735) 
(n=12), Barrier et al data (PMID 16966692) (n=50), Barrier et al data (PMID 17043639) (n=24), and 
drug response on NCI-609 data (n=34) independently. Further, time-dependent ROC analysis was done to 
get an estimate of the discriminatory powers of the identified gene signatures. Prediction models were 
built with the 3-gene signature and the 5-gene signature using classifiers in Weka10
                                                     
9 http://discover.nci.nih.gov/cellminer/loadDownload.do 
10 http://www.cs.waikato.ac.nz/ml/weka/ 
 to predict recurrence 





patient stratification into low-risk and high-risk groups (p < 0.05, n=73, log-rank tests,) with distinct 
relapse-free survival and overall survival, respectively. Kaplan-Meier analysis using the 5-gene signature 
generated significant patient stratification into low-risk and high-risk groups (p < 0.05, n=73, log-rank 
tests) with distinct relapse-free survival and overall survival, respectively. When the 3-gene and 5-gene 
signatures were compared over multiple datasets the 3-gene signature had improved prediction accuracy. 
But the difference in the prediction accuracies was not statistically significant. From these results it can be 
concluded that it is possible to build prognostic models based on the microarray gene expression data to 
identify patients at high-risk of recurrence. The identified gene signatures were validated on rectal cancer 
data and they generated significant patient stratification into low-risk and high-risk groups. 
  
This thesis is organized as follows. Chapter 2 discusses the background of our study. Chapter 3 
describes the experimental details of the identification and validation of the 9-gene signature and the 
validation results. Chapter 4 describes the experimental details of identification and validation of the 3-
gene and 5-gene recurrence signatures. Chapter 5 discusses the validation results of all the gene signatures 

















Gene signatures can be used to aid clinical decision-making in personalized therapy. They can also be 
used to stratify patients who would experience recurrence and who would not. The goal of our study is to 
identify a small subset of genes that could potentially be used to predict the likelihood of lymph node 
metastases (stage) and recurrence in patients with colon cancer. Prognostic models can be built based on 
these gene signatures to identify patients at high-risk of recurrence. These gene signatures have the 
potential for improving diagnostic classification, treatment selection, and prognostic assessment. 
 The advent of high-throughput technologies such as DNA microarrays is currently 
revolutionizing biology and medicine. Machine learning techniques are playing a pivotal role in analyzing 
the generated microarray data. Machine learning algorithms are very useful in cancer research and several 
machine learning algorithms have already been successfully applied on microarray gene expression data 
to classify tumors, predict disease outcome and treatment response (8). Unsupervised machine learning 
approaches such as, self-organizing maps (SOM) were used to organize genes into biologically relevant 
clusters in leukemia (11), and hierarchical clustering was used to classify colon cancer tissues into 
cancerous and non-cancerous based on the gene expression (9). Supervised machine learning techniques 
such as Support vector machines (SVMs) were used for multi-class cancer diagnosis (10). Nearest 
shrunken centroids were used for diagnosing cancer (38). Decision trees and feed-forward neural 
networks were used for lung cancer classification (39). 
 The remainder of this chapter is organized as follows. Section 2.2 describes the feature selection 
techniques utilized in this study. Section 2.3 describes the classification algorithms used in this study. 





analysis. Section 2.6 presents the related work performed in previous studies. Section 2.7 discusses the 
open problems in this area, and Section 2.8 summarizes this chapter. 
2.2 Feature selection techniques 
Two of the most important problems in microarray data analysis relate to the dimensionality of the data 
and noise. In many bioinformatics problems, the number of features is significantly larger than the 
number of samples (high feature to sample ratio). Moreover, not all the features are necessary for 
classification purposes. Inclusion of all the features would contribute noise and introduce an error. 
 Feature selection is the process of systematically reducing the dimensionality of a dataset to an 
optimal subset of attributes for classification purposes. The main idea of feature selection is to choose a 
subset of input variables. Feature selection can significantly improve the comprehensibility of the 
resulting classifier models by eliminating features with little or no predictive information. Several 
commonly used feature selection techniques like Random forests, Information gain attribute evaluator, 
CfsSubset evaluator, GainRatio evaluator, and ReliefF attribute evaluator are described as follows. 
2.2.1 Variable selection using Random forests 
 
Random forests are an ensemble method that combines several individual classification trees. In order to 
grow these ensembles, random vectors are generated that govern the growth of each tree in the ensemble. 
The basic step of random forests is to form diverse tree classifiers from a single training set. Each tree is 
built upon a “bootstrap sample” taken from the training set. A random subset from the whole set of 
variables are used for splitting the tree nodes. The classification decision of a new case is obtained by 
majority voting over all trees unless the cut-off value is user defined. In random forests, about one-third 
of the cases in the bootstrap sample are not used in growing the tree. These cases are called “out-of-bag” 
(OOB) cases and are used in evaluating the performance of the algorithm.  
Random forest returns several measures of variable importance. The most reliable measure is the 





the difference between the “out-of-bag” error rate for the randomly permuted mth variable (the error rate 
obtained by randomly rearranging the values of the mth variable for the out-of-bag set, for each tree, 
and getting new classifications for the forest, by putting this permuted set down the tree) and the 
original “out-of-bag” error rate (41). Based on the “mean decrease in accuracy” measure, backward 
elimination was used to identify the gene subset with the smallest “out-of-bag” error rate. The OOB error 
rate was used to choose the final set of genes, not to obtain estimates of the error rate. This procedure was 
implemented using the varSelRF11 package in R12




Information gain (InfoGain) attribute evaluator is a supervised attribute filter for selecting attributes. This 
method evaluates the attributes by measuring information gain with respect to class. Numeric attributes 
are first discretized using the MDL-based discretization method13
                                                                                          (Equation 1) 
where  H(X) is the entropy of X, H(Y) is the entropy of Y, and H(X,Y)  is the joint entropy of  X and Y. 
. This method treats missing value as a 
separate value or distributes the counts among other values in proportion to their frequency. It is used in 
conjunction with the Ranker which ranks attributes by their individual evaluations. It is only capable of 
generating attribute rankings (12). The user can specify the number of attributes to retain and the 
threshold can be adjusted to discard the attributes.  
The information gain of a given attribute X with respect to the class attribute Y is given by: 
2.2.3 CfsSubset evaluator 
Subset evaluators take a subset of attributes and return a numeric measure that guides the search. 
CfsSubset evauator assesses the predictive ability of each attribute individually and the degree of 








redundancy among them, preferring sets of attributes that are highly correlated with the class but having 
low inter-correlation. Conditional entropy is used to provide a measure of the correlation between features 
and class and between features. If H(X) is the entropy of a feature X and H(X|Y) the entropy of a feature X 
given the occurrence of feature Y, the correlation between two features X and Y can then be calculated 
using the symmetrical uncertainty as follows: 
                                                                                                                (Equation 2) 
The class of an instance is considered to be a feature. The goodness of a subset is then determined as: 
                                                 (Equation 3) 
where k is the number of features in a subset, rci is the mean feature correlation with the class and rii is the 
mean feature correlation. 
2.2.4 GainRatio attribute evaluator 
GainRatio attribute evaluator evaluates attributes by measuring their gain ratio with respect to the class. 
If X represents the attribute and Y represents the class the GainRatio is given by the following equation: 
                                                                                                        (Equation 4) 
where H(Y) is the entropy of Y, H(X) is the entropy of X, and H(Y/X) is the entropy of Y given X. 
Missing value counts can be distributed across other values in proportion to their frequency or they can be 
treated as separate values. 
2.2.5 ReliefF attribute evaluator 
ReliefF attribute evaluator evaluates the worth of an attribute by repeatedly sampling an instance and 
considering the value of the given attribute for the nearest instance of the same and different class. It can 





classification. It finds one nearest neighbor of I1 from every class. On these neighbors Relief evaluates the 
relevance of every feature f Є F accumulating it into W[f]. The nearest neighbor from the same class is a 
hit H, and from a different class is a miss M(C) of class C. At the end W[f] is divided by m to get the 
average evaluation in [–1, 1].  
 
           (Equation 5) 
The function diff (f;I1; I2) calculates the difference between the values of the attribute A for two instances 
I1 and I2. For nominal attributes it is defined as: 
                                                                     (Equation 6) 
For numerical attributes it is defined as: 
                                                                                      (Equation 7) 
2.3 Classification algorithms 
Machine learning is a subfield of Artificial Intelligence dealing with the development of algorithms that 
learn from past experience. Machine learning techniques are extensively applied to microarray data, 
particularly for diagnostic purposes. Especially in cancer diagnostics, microarray classification tools are 
used for cancer subtype discrimination and outcome prediction. The following section describes the 
machine learning algorithms that we have used in our research for predicting disease subtype and 
outcome, and building prognostic models. 
2.3.1 Bagging 
 
Bagging stands for bootstrap aggregating. Given a training set, the original training data is altered by 





the original dataset to create a new one of the same size. Instead of obtaining independent datasets from 
the domain, bagging just resamples the original training data. Then, a learning scheme like a decision tree 
is applied to each of these derived datasets and the classifiers generated from them vote for the class to be 
predicted. All models receive equal weights and bagging produces a combined model that often performs 
significantly better than the single model built on the original training data (12).  
2.3.2 Naive Bayes 
 
The classifier is named so, because it is based on Baye’s rule and assumes that the attributes are 
independent “naively”. It is particularly suitable when the dimensionality of the inputs is high. Despite its 
simplicity, Naive Bayes can often outperform more sophisticated classification methods. If the data is 
redundant, Naive Bayes classifier works well with some attribute selection procedures that eliminate 
redundant data. The Bayes rule is described as follows. 
If H is the hypothesis and E is the evidence that bears on that hypothesis, then 
 P (H|E) = P(E|H) P(H) / P(E)                       (Equation 8) 
                                             or                                 (Equation 9) 
2.3.3 Threshold selector 
 
Threshold selector is a Meta classifier that selects a threshold on the probability distribution output by a 
classifier. The threshold is set so that a given performance measure is optimized. The performance 
measure is the F-measure14
                                                    (Equation 10) 
 (Equation 3). Performance can be measured either on the training data, on a 
hold-out set, or using cross-validation (12).  
 
 






2.3.4 Locally Weighted Learning (LWL)  
 
LWL belongs to the class of instance-based learners. It assigns weights using an instance-based method 
and builds a classifier from the weighted instances. Attribute normalization is turned on by default. The 
base classifier can be selected by the user. Naive Bayes is a good choice for classification problems. 
Other parameters that can be adjusted are k-nearest neighbor (KNN). This method determines the number 
of neighbors used to determine the width of the weighting function, and the kernel shape to use for 
weighting, which can be linear, inverse, constant or Gaussian (12). 
2.3.5 Multilayer Perceptron 
 
Multilayer Perceptron is a neural network classifier. It belongs to the class of supervised neural networks. 
It is one of the most important and widely used network models. The multi-layer perceptron neural 
network model consists of a network of processing elements or nodes arranged in layers, usually 
interconnected in a feed-forward way. Each neuron in one layer has directed connections to the neurons 
of the subsequent layer. This classifier uses back propagation technique for learning. In MLPs, learning is 
supervised with separate training and recall phases. 
1. The network produces an output pattern for each input pattern. 
2. The actual output is compared with the known output from the training set and the error is 
calculated. 
3. The weights are adjusted to reduce the error. 
4. The steps 1-3 are repeated many times for every instance in the training set until the error is 
minimized. 
Once the network has been trained, the weights are then fixed. The testing set is fed into the network and 







2.3.6 J48  
 
The Weka package implements its own version of C4.5 known as J48. This algorithm induces decision 
trees for classification by using the greedy technique. A decision-tree model is built by analyzing the 
training data and that model is used to classify testing data. If the test data is not available, J48 performs a 
cross-validation using the training data. 
2.3.7 IB1 
 
The IB1 classifier is a 1-nearest neighbor instance-based classifier. It is the simplest instance-based 
learning algorithm. It uses a simple distance measure to find the training instance closest to the given test 
instance and assigns the same class as that of the training instance. If multiple closest instances are found, 
the first one found is used. Generally the distance measure used is the Euclidean distance. An advantage 
of instance-based learning over many other machine learning methods is that new examples can be added 
to the training set at any time. Though instance-based learning is simple and works very well, it is often 
slow (12).  
2.3.8 KStar  
 
KStar is an instance-based classifier, meaning that the class of a test instance is based upon the class of 
those training instance(s) that resemble it most. The resemblance is calculated by using the distance 
function. KStar uses an entropy-based distance function. This way it differs from other instance-based 
classifiers. It belongs to the class of k-nearest neighbor classifiers because it classifies each instance by 
looking at the nearest k data points and determining the class by the one which is the most common in the 
nearest k data points (13). KStar has an option to specify the blend factor which specifies how the 
distance function used to compute the k-nearest neighbors acts. If the blend factor is set to 0%, the 
distance function performs like a standard nearest neighbor classifier by selecting just one instance to 
classify the test instance. If the blend factor is set to 100%, the distance function takes many instances and 





2.3.9 Alternating Decision Tree (AD Tree) 
 
Alternating decision tree is a generalized representation of both voted stumps and decision trees. It uses 
boosting as a method for learning data. AD Tree supports only two-class problems. The number of 
boosting iterations can be manually tuned to suit the dataset and the desired complexity/accuracy tradeoff. 
More boosting iterations result in larger and potentially more accurate trees, but make the learning 
process slower (12). Each of the iterations adds three nodes to the tree (one split node and two prediction 
nodes) unless merging occurs. The default search method is an exhaustive search. Heuristic search 
methods can be used to speed up learning but they are not guaranteed to find an optimal solution. The 
instance data can be saved for visualization. 
2.3.10 AdaboostM1 
 
AdaboostM1 is a variant of Adaboost technique for multi-class problems. Adaboost stands for adaptive 
boosting. Boosting is one type of meta-learning scheme that tries to build a good learning algorithm based 
on a group of weak classifiers. In boosting, weighting is used to give more weight to more successful 
models. It can be applied to any classification learning algorithm. By weighting the instances, the learning 
algorithm can be forced to concentrate on a particular set of instances with more weight. Such instances 
are important because there is a greater incentive to classify them correctly (12). 
2.3.11 Decision Stump 
 
Decision Stump is a weak learner consisting of one-level binary decision tree. It is usually used in 
conjunction with a boosting algorithm. It implements regression based on the mean-squared error or 
classification based on the entropy. 
2.3.12 Multiboost AB 
 
Multiboosting is an extension to the Adaboost technique for forming decision committees. It can be 





bias of Adaboost technique and variance reduction property of wagging. This technique produces lower 
error than Adaboost or wagging. C4.5 is used as the base learner (14).  
2.3.13 JRip 
 
JRip implements a propositional rule learner called the ripper algorithm, an acronym for repeated 
incremental pruning to produce error reduction including heuristic global optimization of the rule set. 
Classes are examined in increasing size and an initial set of rules for the class is generated using 
incremental reduced-error pruning.  
2.3.14 Random Committee 
 
Random Committee builds an ensemble of randomized base classifiers and averages their predictions. 
Each base classifier is based on the same data but uses a different random number seed. This only makes 
sense if the base classifier is randomized, otherwise all classifiers would be the same (12).  
2.3.15 Logistic Regression 
 
This algorithm implements a multinomial logistic regression model with a ridge estimator. Logistic 
regression is a model used for prediction of the probability of occurrence of an event by fitting data into a 
logistic curve. There are some modifications in the implementation compared to the original logistic 
regression which does not deal with instance weights. The algorithm is modified a little bit to handle the 
instance weights (15). Ridge regression is a good method for obtaining more stable parameter estimates 
for the logistic regression model. 
2.4 Survival Analysis 
Survival analysis is a branch of statistics dealing with the death in biological organisms and failure in 
mechanical systems. Survival analysis examines and models the time it takes for events to occur. In our 





be imagined to consist of two parts: the underlying hazard function describes how hazard (risk) changes 
over time and the effect parameters describe how hazard relates to other factors such as the choice of 
treatment, as in a medical scenario. When applied in the area of bioinformatics, survival analysis attempts 
to answer questions such as: what fraction of a population is expected to survive past a certain time? Of 
those that survive, at what rate will they die? Can multiple causes of death be taken into account? How do 
particular circumstances or characteristics increase or decrease the odds of survival? 15
2.4.1 Cox proportional hazards model 
 
Proportional hazards models are a sub-class of survival models in statistics, based on the assumption that 
effect parameters multiply hazard. For example, if taking drug X halves the hazard at time 0, it also 
halves the hazard at time 1, or at time t for any value of t. The effect parameters estimated by any 
proportional hazards model can be reported as hazard ratios. Sir David Cox observed that if the 
proportional hazards assumption holds (or, is assumed to hold) then it is possible to estimate the effect 
parameter(s) without any consideration of the hazard function16
                                                              (Equation 11) 
The baseline hazard function is given as α (t) = log h0(t) 
The above equation represents a semi-parametric model as the baseline hazard model. It can take any 
form where i represents the subscript for observation, x represents the covariates, constant α represents the 
log-baseline hazard. 
. This approach to survival data is called 
application of the Cox proportional hazards model. It is a broadly applicable and the most widely used 
method of survival analysis for exploring the relationship between the survival of a patient and several 
explanatory variables (16).  







                                 or                        (Equation 12) 
Consider two observations i and i’ that differ in their x-values, with the corresponding linear predictors as 
follows:                                   
                                                                                  (Equation 13) 
                                           (Equation 14) 
The hazard ratio for these two observations is as follows: 
                                                      (Equation 15) 
                                                                       (Equation 16) 
Given the survival times, status (alive or dead) and one or more covariates, Cox proportional hazards 
model produces a baseline survival curve, covariate coefficient estimates and their standard errors, risk 
ratios, 95% confidence intervals, and significance levels. A positive regression coefficient implies that the 
hazard is higher and thus the prognosis is worse for higher values. Conversely, a negative regression 
coefficient implies a better prognosis for patients with higher values of that variable. 
2.4.2 Kaplan-Meier curves 
 
Survival curves plot percentage of survival as a function of time. The Kaplan-Meier method is one of the 
techniques used for plotting survival curves. It is used to find out the proportion of the patients living for 
a certain amount of time after the treatment. The advantage of the Kaplan-Meier curve is that it takes into 
account, the “censored” data. A plot of the Kaplan-Meier estimate of the survival function is a series of 
horizontal steps of declining magnitude. In the Kaplan-Meier method, survival is recalculated every time 





 To calculate the fraction of patients who survived in a particular interval of time, divide the 
number alive at the end of the interval by the number alive at the beginning of the interval (excluding any 
censored patient in that interval from both the numerator and the denominator). This method 
automatically accounts for censored patients, as both the numerator and denominator are reduced for the 
interval when a patient is censored (18). 
2.4.2.1 Kaplan-Meier estimator 
Consider that a cohort has n individuals and t1 , t2, t3........denote the actual times of death of the n 
individuals  and d1, d2, d3 …… denote the number of deaths that occur at each of these times. Let n1, n2 
,n3…….be the corresponding number of patients remaining in the cohort. 
                                                 (Equation 17) 
The above equation represents the Kaplan-Meier estimator of the survival function S(t). 
2.4.2.2 Interpretation of Kaplan-Meier Curves 
• The Y- axis represents the estimated probability of survival.  
• Precision of estimates depends on the number of observations, so the estimates on the left-hand 
side are more precise than the ones on the right-hand side. This is due to the less number of 
deaths and censored cases. 
• But if a patient dies during the trial, then the survival curve reflects the patient's death at the 
appropriate time interval with a step down. 
• The curve takes a step down every time a patient dies. 
• The small blips or vertical tick-marks on the curve indicate when (time) the patient has been 
censored. 
• Probability of surviving to any point is estimated from cumulative probability of surviving in 





• There is another effect of censoring on the curve. As the patients are censored it reduces the 
number of patients contributing to the curve, so each death occurring after censoring represents a 
higher proportion of the remaining patients, and so every step down afterwards will be a bit larger 
than it would have been. 
2.4.3 Log-rank test 
 
Log-rank test is used to compare the survival of two groups of patients. Consider a survival plot showing 
two survival curves, one for low-risk group and the other for high-risk group. Looking at the curves, one 
can arrive at a conclusion that the low-risk group differs from the high-risk group (or vice versa) at an 
arbitrary time point, but nothing can be said about the two groups looking at the total survival time span. 
So we use the log-rank test which tells us whether the two groups differ significantly or not. The log-rank 
test is used to test the null hypothesis that there is no difference between the populations in the probability 
of an event (e.g. death) at any time point. A value of p < 0.05 indicates that the difference between the 
two groups is statistically significant. The log-rank test assumes that censoring is unrelated to the 
prognosis, and the survival probabilities are the same for subjects irrespective of the times when they 
were enrolled in the study. It is only a test of significance and it cannot provide an estimate of the 
difference between the groups or a confidence interval (19). 
2.4.4 Time-dependent ROC curves 
 
ROC curves display sensitivity and specificity of a continuous diagnostic marker for a binary disease 
variable. Time-dependent ROC curves take the disease outcome into account and vary as a function of 
time. In our study the binary disease variable R(t) = 1, if the patient had recurrence prior to time t, 
otherwise R(t) = 0. For a diagnostic marker M, both sensitivity and specificity are defined as a function of 
time t, as follows:   
  Sensitivity(c,t)=P{M>c|R(t)=1}                                                                                  (Equation 18) 





A time-dependent ROC curve is a plot of 1 – specificity(c, t) versus sensitivity(c, t) for all possible values 
of threshold c. Sensitivity and specificity can be used to quantify the diagnostic ability of the test. 
Sensitivity is the probability that the test is positive, given that the person has the disease. Specificity is 
the probability that the test is negative, given that the person does not have the disease (20). The higher 
the ROC curve, the better is its capacity for discriminating diseased from non diseased subjects. ROC 
curves can also be used for comparing the discriminatory capacity of different diagnostic markers. In our 
study, the disease status changes with time. Some patients die as time progresses due to the disease or 
recurrence. So, we use time-dependent ROC curves instead of the classical ROC curves. There are 
different estimators for the ROC curves. We use the Kaplan-Meier based simple estimator in our ROC 
analysis. 
2.5 Correlation coefficient 
Correlation coefficient17
                                                 (Equation 20) 
If we have a series of n  measurements of X  and Y  written as xi  and yi  where i = 1, 2, ..., n, then the 
Pearson product-moment correlation coefficient can be used to estimate the correlation of X  and Y . The 
Pearson correlation coefficient is given by the formula mentioned below. 
 indicates the strength of the relationship between two random variables. The 
correlation coefficient ρX,Y between two random variables X and Y with expected values μX and μY and 
standard deviations σX and σY is defined as: 
                                                                                      (Equation 21) 
Correlation analysis is frequently used in microarray data analysis to measure the association between the 
variables. In our research, correlation analysis is used in validating cDNA microarray data by finding the 






correlation between the gene copy number and RNA expression. This might be useful in understanding 
the genomic and proteomic level alterations in patients. 
2.6 Related studies 
Machine learning techniques and algorithms have been applied on microarray data from long time for 
tumor classification, prognosis prediction, and drug response prediction. This section describes some of 
the studies in the areas of tumor classification and prognosis prediction which are relevant to our research.  
 The study by Kwon et al (21) identified the genes involved in the carcinogenesis and progression 
of colorectal cancer by analyzing the gene-expression profiles of colorectal cancer cells using cDNA 
microarray. The samples and genes were classified by using a two way clustering analysis which 
identified genes that were differentially expressed in the cancerous and noncancerous tissues. Genes 
associated with lymph node metastasis were identified by using the k-nearest neighbors method. A 60-
gene predictor correctly classified 10 of 12 patients (83.3%) as having colorectal cancer with lymph node 
metastasis versus those without metastasis. 
 The study by Koehler et al (22) created gene expression profiles from 25 colorectal carcinomas, 
corresponding normal colonic mucosa, and 14 liver metastases using cDNA arrays containing 1176 
cancer related genes. Hierarchical clustering clearly distinguished carcinomas from non-cancerous tissues, 
separated tumors into high-stage and low-stage groups, and correlated with the histopathological 
classification in 87.0% of the cases. Statistical analysis (Mann–Whitney U test) revealed 40 tumor-
specific genes which allowed identification of malignant tissue samples by clustering analysis. A specific 
expression signature in matching metastases was not found, but a set of 23 genes with statistically 
significant expression patterns (p < 0.001) in high and low stage tumors were identified.  
 
 The study by Croner et al (23) calculated the prediction rates for lymphatic metastasis using 





error, specificity, and sensitivity were analyzed using six different statistical classifiers. Analysis of 
conventional parameters produced a positive prediction rate that ranged between 53% and 61%. 
Microarray prediction rates were between 62.0% and 67.0% for lymphatic metastasis. It was concluded 
that the prediction of lymphatic metastasis can be improved by gene expression profiling of the primary 
tumor biopsy alone, or in combination with conventional parameters.  
 The study by Barrier et al (24) aimed at building a prognosis predictor that could be used for both 
stage II and stage III colon cancer patients to identify patients at high-risk of recurrence. The k-nearest 
neighbor classifier was used as a predictor. The main parameters of this classifier, the number of 
informative genes and the nearest neighbors k were chosen using cross validation. For both types of 
predictors (non-neoplastic mucosa and tumor based), 150 different pairs of parameters were considered 
and the performance of the corresponding predictors was assessed using six-fold cross-validation. Based 
on the results of cross validation, a 30-gene tumor based predictor and a 70-gene non-neoplastic mucosa 
based predictor were built on the whole set of patients. As a second set of independent samples was not 
available, a double cross-validation design was used, with an ‘inner level’ six-fold cross-validation for 
parameter selection and an ‘outer level’ three-fold cross-validation for performance assessment of the 
selected predictor. The estimated accuracy of the 30-gene tumor based predictor was 78.0% and that of 
the 70-gene non-neoplastic mucosa based predictor was 83.0%. 
 The study by Barrier et al (25) focused on identifying a subgroup of patients at high-risk of 
recurrence who were more likely to benefit from adjuvant chemotherapy based on non-neoplastic mucosa 
microarray gene expression measures of 24 patients (10 with a metachronous metastasis, 14 with no 
recurrence), for stage II colon cancer patients. The gene expression data of 24 patients was profiled using 
the Affymetrix HGU133A Gene Chip. A 70-gene prognosis predictor was identified, by selecting the 70 
most differentially expressed genes (the number of genes to include was set to 70 based on the previous 





gene set with a mean prognosis prediction accuracy of 81.8%, a sensitivity of 73.0%, and a specificity of 
87.1% on the validation set.  
 
 The study by Bandres et al (5) aimed at identifying patients at high-risk of recurrence within the 
group of Duke’s stage B patients. Tumor gene expression profiles from patients with Duke’s B colorectal 
cancer were analyzed by high density oligonucleotide microarrays. The results showed that a subset of 48 
genes were differentially expressed with an associated probability P < 0.001 in the t-test18
2.7 Open Problems 
. Another 11 
genes, separating both the groups were identified using the Fisher criterion. Finally, 8 genes common in 
both the subsets were selected. The 8-gene signature was associated with relapse in Duke’s stage B colon 
cancer patients, and it was able to discriminate between relapsed and non-relapsed patients. Furthermore, 
the differential expression of five genes (CHD2, RPS5, ZNF148, BRI3 and MGC23401) in colon cancer 
progression was confirmed by real-time PCR in an independent set of patients of Duke’s B and C stages. 
Microarray gene expression data is high dimensional, typically containing tens of thousands of features 
and a small sample size. Many of the genes contain irrelevant information which is not necessary for 
classification of the disease or phenotypes. Inclusion of these irrelevant genes increases the 
dimensionality of the dataset, introduces noise, and increases the computation time due to the complex 
search space. The data we analyzed in this study consisted of 73 observations of the expression levels of 
each of the 10,220 genes. Due to the very few observations and many features, innovative feature 
selection schemes need to be developed. Most of the studies described in the previous section explored 
the microarray gene expression data by using a single feature selection technique. Usually, a single 
feature selection technique is not enough to identify powerful gene signatures predicting the disease 
outcome given the high dimensional nature of the microarray data. Hence, we developed a combinatorial 
scheme to identify gene signatures. In the first step, we use random forests for variable selection. In the 






second step, different attribute selection schemes in Weka such as CfsSubset, GainRatio, InfoGain and 
Relief were tested to reduce the feature set size by dropping some lower ranked features. It was found that 
the combination of random forests and InfoGain yielded the best results. This combinatorial feature 
selection scheme using random forests and InfoGain yields an optimal feature subspace which 
differentiates well between the classes in our study. 
2.8 Summary 
This chapter described the variable selection methods using random forests, various classification 
algorithms used in the study, the techniques used in survival analysis, the correlation coefficient analysis, 
related studies and open problems. The following chapters describe in detail how these techniques were 
applied on Ried et al colon cancer data to identify gene signatures, and results on independent colon 















Lymph node metastasis prediction model 
3.1 Introduction 
Accurately predicting the lymph node status or the stage of a cancer patient helps in selecting the optimal 
treatment. Staging is an important prognostic factor in determining the treatment options. The 5-year 
survival rate19
 Microarray gene expression data is highly correlated and many of the genes contain irrelevant 
information which is not necessary for classification of the disease or phenotypes. So, t-test
 in colon cancer patients with stage II tumors is ~78% and stage III tumors is ~64%. When 
a patient has been diagnosed with cancer, various clinical parameters are used to assess the risk of 
metastasis and death. In spite of the numerous advances in this area, tumor stage cannot be accurately 
determined by morphological assessment. With the advent of cDNA microarray technology, it is possible 
to measure the expression levels of thousands of genes simultaneously. Molecular markers identified 
based on the cDNA microarray gene expression data, have the ability to detect differences between the 
tumors at the molecular level (38). They offer improved prognostic accuracy when compared to the 
traditional methods. Patients at high-risk of metastasis can be identified and treated aggressively, while 
sparing other patients from the harmful effects of the invasive treatment. This chapter focuses on the 
identification and validation of the 9-gene lymph node status signature based on the microarray gene 
expression data in colon cancer patients. 
20
                                                     
19 http://www.webmd.com/colorectal-cancer/guide/treatment-stage 
20 http://www.socialresearchmethods.net/kb/stat_t.php 
 was done on 
genes with more than 5 missing values to evaluate the difference in proportions of missing values in node 
positive versus negative groups. Genes passing the t-test along with all genes having less than 5 missing 
values, a total of 10,220 genes were included for further analysis. We used a novel technique to identify 





which identified a set of 14 genes. In the next step, the genes that did not have differential expression in 
lymph node negative versus positive tumors were discarded, leading to the identification of the 9-gene 
signature.  
 The discriminatory power of the 9-gene signature was evaluated by time-dependent ROC. The 
area under curve (AUC) was 0.85 and 0.86 for relapse-free survival (RFS) and overall survival (OS), 
respectively. The 9-gene signature generated significant patient stratification into low-risk and high-risk 
groups with distinct (p=1e-04, n=73, log-rank tests) and (p=0.043, n=73, log-rank tests) relapse-free 
survival (RFS) and overall survival (OS), respectively. 
 The remainder of this chapter is organized as follows. Section 3.2 introduces the data sets used 
for validation in the experiments. Section 3.3 introduces our study design and experiments in detail. 
Section 3.4 describes the validation results on multiple colon cancer datasets. Section 3.5 describes the 
correlation analysis, and Section 3.6 summarizes this chapter. 
3.2 Description of the data sets 
Ried et al PMID 17210682: The colon cancer microarray data from Ried et al contained 22,464 genes 
and 73 patient samples, all of them treated for primary adenocarcinomas of the colon. Of these 33 tumor 
samples were stage II (lymph node negative) and 40 tumor samples were stage III (lymph node positive). 
The relapse-free survival (RFS), overall survival (OS), and recurrence information was available for each 
of the patients in this dataset (2).  
Koinuma et al PMID 16247484: The data used in this study was obtained from 10 specimens from each 
group (MSI - and MSI +) subjected to gene expression profiling with microarrays. Affymetrix Gene Chip 
Human Genome U133 Array Set HG-U133 A and B was used in this analysis. The clinical information 
consisted of the Duke’s stage for each of the patients (27).  





Duke’s Stage B      lymph node negative (class b) 
Duke’s Stage C      lymph node positive (class a) 
Duke’s Stage D     these samples were not considered for leave-one-out cross validation. 
Barrier et al PMID 16091735: This colon cancer data set consisted of 18 patient samples and 22,283 
genes. The recurrence status (yes/no) was the available clinical information. Nine of the 18 patients 
developed a distant metastasis in the follow-up and the other nine patients remained disease-free for at 
least 5 years. All the patients were operated on for colonic adenocarcinomas. Ten patients had no lymph 
node metastasis (stage II) and did not receive any chemotherapy. The other eight patients had lymph node 
metastasis (stage III) and received 6-month adjuvant chemotherapy with fluorouracil (FU) and 
levamisole (24).  
Barrier et al PMID 16966692: This colon cancer data set consisted of 50 patient samples and 22,283 
genes. The recurrence status (yes/no) within 5 years was available in clinical data. Twenty-five patients 
developed a distant metastasis in the follow-up and the other 25 patients remained disease-free for at least 
5 years. All the fifty patients were operated on for a stage II colon adenocarcinoma and none of the 
patients received any adjuvant chemotherapy (28).  
Barrier et al PMID 17043639: This colon cancer data set consisted of 24 patients and 22,283 genes. The 
recurrence status (yes/no) within 5 years was also given. Ten patients developed a liver metastasis after 
surgery and the other 14 patients remained disease-free for at least 5 years. All the twenty-four patients 
were operated on for stage II colon adenocarcinomas and none of these 24 patients received any adjuvant 
chemotherapy (25).  
NCI-60 data: The NCI-6021
                                                     
21 http://discover.nci.nih.gov/cellminer/loadDownload.do 
 data contains a panel of 60 diverse human cancer cell lines used by the 
Developmental Therapeutics Program of the U.S. National Cancer Institute to screen >100,000 





Affymetrix HG-U133A and HG-U133B chips. The drug activity data of 5-FU (fluorouracil) on all the 60 
cell lines is available for download online22
                                                     
22 http://discover.nci.nih.gov/nature2000/data/selected_data/dataviewer.jsp?baseFileName=a_matrix118&nsc=2&dataStart=3 
.  
Defining drug sensitivity and resistance: The drug activity profiles of 118 cancer agents including 5-FU 
are available online. 5-FU is the drug frequently used in colon cancer treatment. The recorded drug 
activities (log10 GI50) were available for the 60 human cancer cell lines. Specifically, for each drug, log10 
(GI50) values were normalized across the 60 cell lines. Cell lines with log10 (GI50) at least 0.5 SD above 
the mean were defined as resistant to the drug. Those with log10  (GI50) at least 0.5 SD below the mean 
were defined as sensitive to the drug. The remaining cell lines with log10 (GI50) within 0.5 SD were 
defined as intermediate in the range of drug responses (41). Specifically, 17 cell lines were sensitive, 26 








































Figure 3.1 Block diagram of the study for 9-gene signature. 
Applying random forests using varSelRF package 
in R software on the training set  
 
Colon cancer data from Ried et al (n=73) 
Applying t-test on genes having > 5 missing values to determine differential gene 
expression in lymph node negative versus positive patients 
 
Missing value replacement using knn algorithm 
on the training set (k=10) 
Randomly splitting data in 2:1 ratio as training 
(n=50) and testing sets (n=23) 
Selecting the genes passing t-test and all other genes 
with ≤ 5 missing values 
14-gene signature 
Validation on testing dataset and other colon cancer datasets, 
plotting Time-dependent ROC, Kaplan-Meier plots 
Removing the genes that did not have differential expression 






3.3.1 Experimental procedure 
 
Data Source The colon cancer microarray data from Ried et al. (2) contained 22,464 genes and 73 patient 
samples, all of them treated for primary adenocarcinomas of the colon. Of these 33 tumor samples were 
stage II (lymph node negative) and 40 tumor samples were stage III (lymph node positive). 
Log Ratio Every spot on the microarray provides two intensity values each of them associated with a 
specific channel. Dividing one intensity by the other gives the expression ratio. We use log ratios as they 
are lot easier to work with than the regular ratios. The log ratio (532/635) was considered for this analysis. 
It is the log (base 2) transformation of the ratio of medians at wavelengths of 532nm and 635 nm.  
Data Preprocessing - t test We investigated whether the observed difference between the two groups 
(node positive versus negative) represents a real difference in the total study population from which the 
sample was drawn, or whether it just occurred by chance (due to sampling variation), by using t-test. The 
number of missing values for each gene was found and t-test was done on genes with more than 5 missing 
values to evaluate the difference in the proportions of missing values in node positive versus negative 
groups.  The genes passing the t-test (p < 0.05, two-sided) were included along with all genes having less 
than 5 missing values for further processing. A total of 10,220 genes satisfied this condition. 
Training dataset The data obtained in the above step was randomly split in 2:1 ratio as training set and 
testing set. The expression data of the 10,220 genes and 50 patients constituted the training set. 
Missing value replacement The training dataset contained missing values. They were replaced using the 
EMV23
                                                     
23 http://cran.r-project.org/web/packages/EMV/index.html 
 package in R software with k=10. This technique estimates the missing values based on the k-
nearest neighbors algorithm. This algorithm selects the k nearest rows that do not contain any missing 
values to the one containing at least one missing value based on the Euclidian distance. Then the missing 






Table 3.1 The 14-gene lymph node status signature. 
 package in R was used in a series of steps on the training dataset 
to find the important features. Lymph node status was used as the class variable. In the first step, a forest 
with N trees was built and the features were ranked according to the importance of the variables. In the 
second step, 20% of the variables that were least important were removed and a new forest was 
constructed with K trees. This step was repeated till there were two genes left. In the experiment, a value 
of N = 2000 and K =1000 were considered, because a large number of trees in the initial forests is likely 
to produce stable importance measures (23). After fitting all forests, the OOB error rates from all the 
fitted random forests were examined and a set of 15 genes leading to the smallest error rate were selected. 
There was a control gene in the identified 15 genes which was discarded leaving 14 genes. Table 3.1 
shows the 14 genes. 
GENE NAME ID 
SNRPD3-small nuclear  ribonucleoprotein H200000411 
IFRG28-28kD interferon responsive pro H200004627 
PDCD5-programmed cell death 5 H200007687 
PLXNB2-plexin B2, mRNA H200000861 
HIST1H3I-histone 1,H3i,m H200013045 
DC50-hypothetical protein DC50 H200019106 
SR140-U2-associated SR140 protein H200020644 
FLJ11078-hypothetical protein FLJ1107 H200016227 
MGC16044-hypothetical protein MGC1604 H200020589 
RNF6-ring finger protein (C3H2C3 type) H200004174 
POU6F2-POU domain, class 6,transcript H200015474 
LAMB1-laminin,beta 1(LAMB1), mRNA H200006892 
ITGB1-integrin,beta1 (fibronectin) H200021334 











3.3.2 Differentially expressed genes 
Differentially expressed genes or discriminator genes are the genes with significantly different expression 
in the two user defined groups or between samples obtained under different conditions in a gene 
expression experiment. These gene signatures or disease associated markers are relevant to biological 
processes. To find the differentially expressed genes, the mean expression values for each of the 14 genes 
were calculated for lymph node negative and positive tumor groups separately. If the gene had a higher 
value in node positive versus negative samples it was over expressed and vice versa. Table 3.2 shows the 
over expressed and under expressed genes, and p-values for each gene obtained using the z-test25
Table 3.2 Over expressed and under expressed genes in the 14-gene signature between lymph node 
positive and negative patients. 
. The 
genes that did not have differential expression among lymph node negative and positive patients, namely, 
PDCD5, HIST1H3I, SR140, LAMB1, and HIST1H2BO in the 14-gene signature were removed. Table 3.3 
shows the remaining 9 genes. 
GENE NAME Category in lymph node positive group p-value Significance 
SNRPD3-small nuclear  ribonucleoprotein Under expressed 0.041134 Yes 
IFRG28-28kD interferon responsive pro Under expressed 0.044768 Yes 
PDCD5-programmed cell death 5 Under expressed 0.062525 No 
PLXNB2-plexin B2, mRNA Under expressed 0.038442 Yes 
HIST1H3I-histone 1,H3i,m Under expressed 0.103315 No 
DC50-hypothetical protein DC50 Under expressed 0.003831 Yes 
SR140-U2-associated SR140 protein Over expressed 0.152485 No 
FLJ11078-hypothetical protein FLJ1107 Under expressed 0.002202 Yes 
MGC16044-hypothetical protein MGC1604 Over expressed 0.006503 Yes 
RNF6-ring finger protein (C3H2C3 type) Over expressed 0.008206 Yes 
POU6F2-POU domain, class 6,transcript Over expressed 0.002299 Yes 
LAMB1-laminin,beta 1(LAMB1), mRNA Under expressed 0.166319 No 
ITGB1-integrin,beta1 (fibronectin) Over expressed 0.012588 Yes 










Table 3.3 The 9-gene signature for predicting lymph node metastasis. 
GENE NAME ID 
SNRPD3-small nuclear  ribonucleoprotein H200000411 
IFRG28-28kD interferon responsive pro H200004627 
PLXNB2-plexin B2, mRNA H200000861 
DC50-hypothetical protein DC50 H200019106 
FLJ11078-hypothetical protein FLJ1107 H200016227 
MGC16044-hypothetical protein MGC1604 H200020589 
RNF6-ring finger protein (C3H2C3 type) H200004174 
POU6F2-POU domain, class 6,transcript H200015474 
ITGB1-integrin,beta1 (fibronectin) H200021334 
3.4 Results 
3.4.1 Validation of the 9-gene signature on testing data (n=23) 
The original data was split in 2:1 ratio as training and testing datasets, respectively. The testing data 
consisted of 23 tumor samples. Eleven tumor samples were lymph node negative and the other 11 
samples were lymph node positive. The data used for validation consisted of the expression of the 9-gene 
signature in the 23 patient samples. Weka software was used for validation and lymph node status 
(negative/positive) was predicted. Different classification schemes including J48, Logistic regression, 
KStar, Threshold selector, and Multilayer perceptron were applied to this dataset to find the best scheme. 
Table 3.4 shows the comparison between J48 and some of the classifiers used for validation on other 
datasets. J48 classifier performed better than the other classifiers. It had a sensitivity of 75.00%, a 
specificity of 81.80%, and an overall accuracy of 78.26%. Table 3.5 shows the confusion matrix for J48 
classifier. The difference in overall accuracy between J48 and other classifiers was not statistically 








Table 3.4 Comparison of accuracies obtained from different classifiers for predicting lymph node 
status using the 9-gene signature. The improved overall accuracy of the prediction with the J48 
classifier compared with other methods was assessed by significance testing (N = 23). 










J48 75.00 81.80 78.40 78.26  
Logistic regression 66.70 54.50 60.60 60.86 <0.11 
KStar 66.70 54.50 60.60 60.86 <0.11 
Threshold selector 58.30 72.70 65.50 65.21 <0.17 
Multilayer perceptron 66.70 45.50 56.10 56.52 <0.06 
 
Table 3.5 Confusion matrix obtained from the J48 classifier for predicting lymph node status using 
the 9-gene signature. 
Actual/Predicted a (node negative) b (node positive) 
a (node negative) 9 2 
b (node positive) 3 9 
 
3.4.2 Time-dependent ROC analyses on data from Ried et al (n=73) 
To explore whether the 9-gene lymph node signature could predict patient disease-free survival and 
overall survival, the survival and status information along with the expression data of the 9 genes are used 
for getting the time-dependent ROC plots. The accuracy of 5-year relapse-free survival prediction using 
these 9 genes is 0.85 and 5-year overall survival prediction is 0.86, as represented by the AUC. 
             
 
Figure 3.2 Time-dependent ROC plots on data from Ried et al (n=73) for relapse-free survival and 





3.4.3 Kaplan-Meier analyses on data from Ried et al (n=73) 
The Cox model based on the expression of the 9-gene signature was used to get recurrence risk scores for 
all the 73 patients. The choices for choosing a cut-off value for patient stratification are the peak value 
from histogram, mean risk score or median risk score. In this analysis, the peak value from histogram was 
chosen as cut-off as it resulted in best patient stratification. Cut-off values of 4.0 and 0.5 were chosen for 
relapse-free survival and overall survival, respectively. The pamr package in R was used to plot the 
Kaplan-Meier curves, for relapse-free survival and overall survival. The low-risk and high-risk groups 
had distinct relapse-free survival (p = 1e-04, n=73, log-rank tests) and overall survival (p = 0.043, n=73, 
log-rank tests). 
             
Figure 3.3 Histograms of risk scores obtained from Cox model for relapse-free survival and overall 






                         
 
Figure 3.4 Kaplan-Meier plots on data from Ried et al (n=73) for relapse-free survival and overall 
survival using the 9-gene signature. 
 
Out of the 73 patients in the colon cancer data from Ried et al, 26 patients remained relapse-free for more 
than 5 years and 10 patients experienced recurrence within 5 years after surgery. To test the performance 
of the identified 9-gene signature, the subgroups obtained for the above group of 36 patients from the Cox 
model were compared with their actual clinical outcomes. Table 3.6 shows the different parameters 
obtained from the Cox model, using the 9-gene signature for relapse-free survival and overall survival, 
respectively. Tables 3.7 and 3.8, show the comparison of predicted clinical outcome for patients with their 
actual follow-up information, for relapse-free survival and overall survival, respectively. The Cox model 
had a sensitivity of 60.0%, a specificity of 92.3%, and an overall accuracy of 83.3%, for predicting 
relapse-free survival. In predicting overall survival, it had a sensitivity of 75.0%, a specificity of 45.8%, 










Table 3.6 Different parameters obtained from the Cox model using the 9-gene signature for 
predicting relapse-free survival and overall survival. 
 



















SNRPD3 2.661 14.304 1.326 2.006 0.045 0.065 1.068 0.793 0.082 0.93 
IFRG28 0.769 2.157 0.382 2.012 0.044 0.122 1.131 0.235 0.521 0.60 
PLXNB2 -3.121 0.044 1.305 -2.391 0.017 -0.516 0.597 0.596 -0.866 0.39 
DC50 -2.476 0.084 0.797 -3.107 0.001 -0.535 0.586 0.459 -1.166 0.24 
FLJ11078 0.600 1.822 0.584 1.028 0.300 0.002 1.002 0.362 0.005 1.00 
MGC16044 0.525 1.690 0.380 1.382 0.170 0.145 1.157 0.269 0.542 0.59 
RNF6 -1.163 0.312 0.815 -1.426 0.150 0.145 0.574 0.465 -1.193 0.23 
POU6F2 0.869 2.384 1.179 0.737 0.460 0.596 1.816 0.581 1.026 0.30 
ITGB1 1.612 5.013 1.237 1.303 0.190 0.465 1.592 0.603 0.771 0.44 
 
Table 3.7 Comparison of the sub groups predicted from the Cox model using the 9-gene signature 
with the actual subgroups for relapse-free survival. 
 
 Recurrence No recurrence Sensitivity (%) Specificity (%) Overall accuracy (%) 
Recurrence 6 4 60.0 92.3 83.3 No recurrence 2 24 
 
Table 3.8 Comparison of the sub groups predicted from the Cox model using the 9-gene signature 
with the actual subgroups for overall survival. 
 
 Death Alive Sensitivity (%) Specificity (%) Overall accuracy (%) 
Death 15 5 75.0 45.8 59.0 Alive 13 11 
 
The Cox model was used for stratifying all the 73 patients in Ried et al data, into low-risk and high-risk 
groups, based on the 9-gene signature. Out of the 73 patients, a total of 37 did not have recurrence with 
survival times less than 5 years. Twenty-nine patients had overall survival times less than 5 years without 
any event (death). The relapse outcome for the 37 patients and the overall survival outcome for the 29 
patients is currently unknown. Table 3.9 shows the prospective prognostic predictions of these patients 
obtained from the Cox model for relapse-free survival and overall survival, respectively. The follow-up 
information for these patients is being collected. When it becomes available in the future, the predictions 






Table 3.9 Patient subgroups obtained from the Cox model for relapse-free survival and overall 






Number Patient ID 
Predicted group by     
Cox model (RFS) Patient ID 
Predicted group by 
 Cox model (OS) 
1  CC-P1 Low Risk CC-P1 Low Risk 
2 CC-P2 Low Risk CC-P4 Low Risk 
3 CC-P4 Low Risk CC-P7 High Risk 
4 CC-P7 Low Risk CC-P8 Low Risk 
5 CC-P8 Low Risk CC-P9 Low Risk 
6 CC-P10 High Risk CC-P11 High Risk 
7 CC-P13 Low Risk CC-P13 Low Risk 
8 CC-P18 Low Risk CC-P16 Low Risk 
9 CC-P20 Low Risk CC-P18 Low Risk 
10 CC-P21 Low Risk CC-P20 Low Risk 
11 CC-P22 Low Risk CC-P21 Low Risk 
12 CC-P23 Low Risk CC-P22 Low Risk 
13 CC-P25 Low Risk CC-P25 Low Risk 
14 CC-P28 Low Risk CC-P28 Low Risk 
15 CC-P29 High Risk CC-P31 High Risk 
16 CC-P31 Low Risk CC-P35 High Risk 
17 CC-P34 Low Risk CC-P36 High Risk 
18 CC-P35 Low Risk CC-P37 High Risk 
19 CC-P37 Low Risk CC-P38 Low Risk 
20 CC-P38 Low Risk CC-P40 High Risk 
21 CC-P40 High Risk CC-P48 High Risk 
22 CC-P42 Low Risk CC-P50 High Risk 
23 CC-P44 Low Risk CC-P51 Low Risk 
24 CC-P46 Low Risk CC-P60 Low Risk 
25 CC-P47 Low Risk CC-P62 Low Risk 
26 CC-P48 Low Risk CC-P66 High Risk 
27 CC-P50 Low Risk CC-P71 High Risk 
28 CC-P51 Low Risk CC-P72 Low Risk 
29 CC-P55 Low Risk CC-P73 High Risk 
30 CC-P56 Low Risk   
31 CC-P60 Low Risk   
32 CC-P62 Low Risk   
33 CC-P66 Low Risk   
34 CC-P68 Low Risk   
35 CC-P70 Low Risk   
36 CC-P71 Low Risk   
37 CC-P72 Low Risk   





3.4.4 External validation of the 9-gene signature on other colon cancer data 
 
This part of the study sought to explore the extent to which the 9-gene signature could be used for 
prediction of lymph node status, recurrence, and drug response in publicly available independent datasets. 
More than 50 classifiers available in Weka software were tested using a leave-one-out cross validation 
technique on each of the independent datasets to find a suitable classification scheme for validation. Due 
to the different number of attributes (matching genes), sample sizes and prediction variables one specific 
scheme could not be used for validation on all the datasets. Different classifiers had to be employed on 
the validation datasets to get fair prediction accuracy. As far as possible the same set of classifiers were 
presented in the comparison tables of validation datasets to provide a fair evaluation of the performance. 
The exact same set of classifiers could not be compared over all the validation datasets due to poor 
performances of classifiers on some datasets and good performances on other datasets. The following 
sections discuss the validation results and comparisons of various classifiers on the independent datasets 
in detail. 
3.4.4.1 Predicting lymph node status by leave-one-out cross validation on data from 
Koinuma et al (n=17) PMID 16247484 
 
The data from Koinuma et al (Affymetrix HG U133 A platform) consisted of 20 patient samples of which 
3 patients were Duke’s stage D. The Duke’s stage D patients were not considered for validation. The 
search for matching genes was done using the Affymetrix ids. There were 7 matching genes (Table 3.10). 
The data used for validation consisted of the expression of these 7 genes in the 17 patients. Weka 
software was used for cross validation and the lymph node status (positive/negative) was predicted. 
Different classification schemes including Naïve Bayes, LWL, JRip, Bagging, and KStar were applied to 
this dataset to find the best scheme. Table 3.11 shows the comparison between Naïve Bayes and some of 
the classifiers used for validation on other datasets. Naive Bayes classifier performed better than the other 





Table 3.12 shows the confusion matrix for Naïve Bayes classifier. The difference in overall accuracy 
between Naïve Bayes and other classifiers was not statistically significant due to the small sample size. 
Table 3.10 Matching genes in Koinuma et al data. 
GENE NAME  ID 
SNRPD3-small nuclear  ribonucleoprotein H200000411 
IFRG28-28kD interferon responsive pro H200004627 
PLXNB2-plexin B2, mRNA H200000861 
FLJ11078-hypothetical protein FLJ1107 H200016227 
RNF6-ring finger protein (C3H2C3 type) H200004174 
POU6F2-POU domain, class 6,transcript H200015474 
ITGB1-integrin,beta1 (fibronectin)  H200021334 
 
Table 3.11 Comparison of accuracies obtained from different classifiers for predicting lymph node 
status using the 9-gene signature. The improved overall accuracy of the prediction with the Naïve 
Bayes classifier compared with other methods was assessed by significance testing (N = 17). 










Naïve Bayes 100.00 75.00 87.50 82.35  
LWL 71.40 70.00 70.70 70.58 < 0.21 
JRip 57.10 70.00 63.55 64.70 < 0.13 
Bagging 57.10 70.00 63.55 64.70 < 0.13 
KStar 42.90 70.00 56.45 58.82 < 0.07 
 
Table 3.12 Confusion matrix obtained from the Naïve Bayes classifier for predicting lymph node 
status using the 9-gene signature. 
Actual/Predicted a (node positive) b (node negative) 
a (node positive) 7 0 
b (node negative) 3 7 
 
3.4.4.2 Predicting recurrence by leave-one-out cross validation on data from Barrier et al 
(n=18) PMID 16091735 
 
The data from Barrier et al (PMID 16091735) consisted of 22,283 genes and 18 patient samples. The 
search for matching genes was done using the Affymetrix ids. There were 7 matching genes (Table 3.13). 
The data used for validation consisted of the expression of these 7 genes in the 18 patient samples. Weka 





including Naïve Bayes, KStar, Multilayer perceptron, JRip, and Logistic regression were applied to this 
dataset to find the best scheme. Table 3.14 shows the comparison between Naïve Bayes and some of the 
classifiers used for validation on other datasets. Naive Bayes classifier performed better than the other 
classifiers. It had a sensitivity of 100.00%, a specificity of 88.90%, and an overall accuracy of 94.44%. 
Table 3.15 shows the confusion matrix for Naïve Bayes classifier. The difference in overall accuracy 
between Naïve Bayes and other classifiers was not statistically significant due to the small sample size. 
Table 3.13 Matching genes in Barrier et al data. 
GENE NAME  ID 
SNRPD3-small nuclear  ribonucleoprotein H200000411 
IFRG28-28kD interferon responsive pro H200004627 
PLXNB2-plexin B2, mRNA H200000861 
FLJ11078-hypothetical protein FLJ1107 H200016227 
RNF6-ring finger protein (C3H2C3 type) H200004174 
POU6F2-POU domain, class 6,transcript H200015474 
ITGB1-integrin,beta1 (fibronectin) H200021334 
 
Table 3.14 Comparison of accuracies obtained from different classifiers for predicting recurrence 
using the 9-gene signature. The improved overall accuracy of the prediction with the Naïve Bayes 
classifier compared with other methods was assessed by significance testing (N = 18).  










NaiveBayes 100.00 88.90 94.45 94.44  
KStar 100.00 66.70 53.35 83.33 < 0.15 
Multilayer perceptron 88.90 77.80 83.35 83.33 < 0.15 
JRip 88.90 66.70 77.80 77.77 < 0.08 
Logistic regression 88.90 66.70 77.80 77.77 < 0.08 
 
Table 3.15 Confusion matrix obtained from the Naïve Bayes classifier for predicting recurrence 
using the 9-gene signature. 
Actual/Predicted a (recurrence) b (no recurrence) 
a (recurrence) 9 0 







3.4.4.3 Predicting recurrence by leave-one-out cross validation on data from Barrier et al 
(n=50) (PMID 16966692) 
 
The data from Barrier et al (PMID 16966692) consisted of 22,283 genes and 50 patient samples. The 
search for matching genes was done using the Affymetrix ids. There were 7 matching genes (Table 3.16). 
The data used for validation consisted of the expression of these 7 genes in the 50 patient samples. Weka 
software was used for validation and recurrence (yes/no) was predicted. Different classification schemes 
including Decision stump, Naïve Bayes, IB1, Logistic regression, and Multilayer perceptron were applied 
to this dataset to find the best scheme. Table 3.17 shows the comparison between Decision stump and 
some of the classifiers used for validation on other datasets. Decision stump classifier performed better 
than the other classifiers. It had a sensitivity of 76.00%, a specificity of 88.00%, and an overall accuracy 
of 82.00%. Table 3.18 shows the confusion matrix for Decision stump classifier. The difference in overall 
accuracy between Decision stump and other classifiers was not statistically significant due to the small 
sample size. 
Table 3.16 Matching genes in Barrier et al data. 
GENE NAME  ID 
SNRPD3-small nuclear  ribonucleoprotein H200000411 
IFRG28-28kD interferon responsive pro H200004627 
PLXNB2-plexin B2, mRNA H200000861 
FLJ11078-hypothetical protein FLJ1107 H200016227 
RNF6-ring finger protein (C3H2C3 type) H200004174 
POU6F2-POU domain, class 6,transcript H200015474 











Table 3.17 Comparison of accuracies obtained from different classifiers for predicting recurrence 
using the 9-gene signature. The improved overall accuracy of the prediction with the Decision 
stump classifier compared with other methods was assessed by significance testing (N = 50).  










Decision stump 76.00 88.00 82.00 82.00  
NaiveBayes 68.00 92.00 80.00 80.00 < 0.40 
IB1 84.00 64.00 74.00 74.00 < 0.16 
Logistic regression 68.00 72.00 70.00 70.00 < 0.08 
Multilayer perceptron 68.00 72.00 70.00 70.00 < 0.08 
 
Table 3.18 Confusion matrix obtained from the Decision stump classifier for predicting recurrence 
using the 9-gene signature. 
Actual/Predicted a (no recurrence) b (recurrence) 
a (no recurrence) 22 3 
b (recurrence) 6 19 
 
3.4.4.4 Predicting recurrence by leave-one-out cross validation on data from Barrier et al 
(n=24) (PMID 17043639) 
 
The data from Barrier et al (PMID 17043639) consisted of 22,283 genes and 24 patient samples. The 
search for matching genes was done using the Affymetrix ids. There were 7 matching genes (Table 3.19). 
The data used for validation consisted of the expression of these 7 genes in the 24 patient samples. Weka 
software was used for validation and recurrence (yes/no) was predicted. Different classification schemes 
including Naïve Bayes, LWL, AD Tree, Random committee, and Multiboost AB were applied to this 
dataset to find the best scheme. Table 3.20 shows the comparison between Naïve Bayes and some of the 
classifiers used for validation on other datasets. Naive Bayes classifier performed better than the other 
classifiers. It had a sensitivity of 50.00%, a specificity of 100.00%, and an overall accuracy of 79.16%. 
Table 3.21 shows the confusion matrix for Naïve Bayes classifier. The difference in overall accuracy 







Table 3.19 Matching genes in Barrier et al data. 
GENE NAME  ID 
SNRPD3-small nuclear  ribonucleoprotein H200000411 
IFRG28-28kD interferon responsive pro H200004627 
PLXNB2-plexin B2, mRNA H200000861 
FLJ11078-hypothetical protein FLJ1107 H200016227 
RNF6-ring finger protein (C3H2C3 type) H200004174 
POU6F2-POU domain, class 6,transcript H200015474 
ITGB1-integrin,beta1 (fibronectin)  H200021334 
 
Table 3.20 Comparison of accuracies obtained from different classifiers for predicting recurrence 
using the 9-gene signature. The improved overall accuracy of the prediction with the Naïve Bayes 
classifier compared with other methods was assessed by significance testing (N = 24).  










NaiveBayes 50.00 100.00 75.00 79.16  
LWL 60.00 78.60 69.30 70.83 < 0.26 
AD Tree 40.00 92.90 66.45 70.83 < 0.26 
Random committee 40.00 85.70 62.85 66.66 < 0.17 
Multiboost AB 50.00 71.40 60.70 62.50 < 0.11 
 
Table 3.21 Confusion matrix obtained from the Naïve Bayes classifier for predicting recurrence 
using the 9-gene signature. 
Actual/Predicted a (no recurrence) b (recurrence) 
a (no recurrence) 14 0 
b (recurrence) 5 5 
 
3.4.4.5 Predicting the response of cell lines in NCI-60 (n=34) (U133A GCRMA) data by 
leave-one-out cross validation 
 
This dataset26
                                                     
26 http://discover.nci.nih.gov/cellminer/loadDownload.do 
 
 consisted of 21,225 genes and 60 cell lines (41). Our focus was on the sensitive and 
resistant cell lines, so cell lines with intermediate response were not considered for validation. A total of 
34 cell lines (17 sensitive and the other 17 resistant to the drug 5-FU) were used in validation. The search 





data used for validation consisted of the expression of these 5 genes in the 34 cell lines. Weka software 
was used for validation and the response (sensitive/resistant) to the drug 5-FU (fluorouracil) was 
predicted. Different classification schemes including Threshold selector, IB1, Logistic regression, 
Random Tree, and Multilayer perceptron were applied to this dataset to find the best scheme. Table 3.23 
shows the comparison between Threshold selector and some of the classifiers used for validation on other 
datasets. Threshold selector performed better than the other classifiers. It had a sensitivity of 94.10%, a 
specificity of 76.50%, and an overall accuracy of 85.29%. Table 3.24 shows the confusion matrix for 
Threshold selector classifier. The difference in overall accuracy between Threshold selector and IB1 (p < 
0.01), Logistic regression (p < 0.01), Random Tree (p < 0.01), Multilayer perceptron (p < 0.01) was 
statistically significant. 
Table 3.22 Matching genes in NCI-60 U133A data. 
GENE NAME  ID 
SNRPD3-small nuclear  ribonucleoprotein H200000411 
PLXNB2-plexin B2, mRNA H200000861 
RNF6-ring finger protein (C3H2C3 type) H200004174 
POU6F2-POU domain, class 6,transcript H200015474 
ITGB1-integrin,beta1 (fibronectin)  H200021334 
 
Table 3.23 Comparison of accuracies obtained from different classifiers for predicting drug 
response using the 9-gene signature. The improved overall accuracy of the prediction with the 
Threshold selector classifier compared with other methods was assessed by significance testing (N = 
34).  










Threshold selector 94.10 76.50 85.30 85.29  
IB1 58.80 52.90 55.85 55.88 < 0.01 
Logistic regression 52.90 47.10 50.00 50.00 < 0.01 
Random Tree 47.10 52.90 50.00 50.00 < 0.01 








Table 3.24 Confusion matrix obtained from the Threshold selector classifier for predicting drug 
response using the 9-gene signature. 
Actual/Predicted a (sensitive) b (resistant) 
a (sensitive) 16 1 
b (resistant) 4 13 
 
3.4.4.6 Predicting the response of cell lines in NCI-60 (n=34) (U133B GCRMA) data by 
leave-one-out cross validation 
This dataset27
Table 3.25 Matching genes in NCI-60 U133B data. 
 consisted of 17910 genes and 60 cell lines (41). Our focus was on the sensitive and resistant 
cell lines, so cell lines with intermediate response were not considered for validation. A total of 34 cell 
lines (17 sensitive and the other 17 resistant to the drug 5-FU) were used in validation. The search for 
matching genes was done using the gene symbols. There was 1 matching gene (Table 3.25). The data 
used for validation consisted of the expression of this gene in the 34 cell lines. Weka software was used 
for validation and the response (sensitive/resistant) for the drug 5-FU (fluorouracil) was predicted. 
Different classification schemes including Threshold selector, Random Tree, Random committee, 
Decision stump, and AD Tree were applied to this dataset to find the best scheme. Table 3.26 shows the 
comparison between Threshold selector and some of the classifiers used for validation on other datasets. 
Threshold selector performed better than the other classifiers. It had a sensitivity of 82.40%, specificity of 
76.50%, and an overall accuracy of 79.41%. Table 3.27 shows the confusion matrix for Threshold 
selector classifier. The difference in overall accuracy between Threshold selector and Random tree (p < 
0.02), Random committee (p < 0.02), Decision stump (p < 0.01), AD Tree (p < 0.01) was statistically 
significant. 
GENE NAME  ID 
POU6F2-POU domain, class 6,transcript H200015474 
 






Table 3.26 Comparison of accuracies obtained from different classifiers for predicting drug 
response using the 9-gene signature. The improved overall accuracy of the prediction with the 
Threshold selector classifier compared with other methods was assessed by significance testing (N = 
34).  










Threshold selector 82.40 76.50 79.45 79.41  
Random Tree 64.70 47.10 55.90 55.88 < 0.02 
Random committee 64.70 47.10 55.90 55.88 < 0.02 
Decision stump 94.10 11.80 52.95 52.94 < 0.01 
AD Tree 52.90 47.10 50.00 50.00 < 0.01 
 
Table 3.27 Confusion matrix obtained from the Threshold selector classifier for predicting drug 
response using the 9-gene signature. 
Actual/Predicted a (sensitive) b (resistant) 
a (sensitive) 14 3 
b (resistant) 4 13 
 
3.4.5 Summary of validation results of 9-gene signature  
 
Table 3.28 shows the details of different validation datasets, predicted variables, classifiers used and 
different accuracies obtained using the 9-gene signature. For each dataset the classifier with the highest 











Table 3.28 Summary of validation results of 9-gene signature on Ried et al data, independent colon 
cancer datasets and NCI-60 data. 











Ried et al testing set 
(n=23)  
PMID 17210682 
J48 Lymph node status 75.00 81.80 78.40 78.26 






node status 100.00 75.00 87.50 82.35 




Bayes Recurrence 100.00 88.90 94.45 94.44 




stump Recurrence 76.00 88.00 82.00 82.00 




Bayes Recurrence 50.00 100.00 75.00 79.16 







94.10 76.50 85.30 85.29 







82.40 76.50 79.45 79.41 
 
3.5 Correlation analysis on CGH and RNA data 
3.5.1 Description of the data sets 
CGH (Comparative genomic hybridization) data: The array CGH data was available only for 29 of the 
73 patient samples. The data consisted of probe name, chromosome name, start and stop coordinates, 
feature number, and description of the genes.  
RNA (Ribonucleic acid) data: The RNA data consisted of 22,464 genes and 73 tumor samples. 
3.5.2 Correlation coefficient analysis on the 9-gene signature 
This study focused on identifying genes in the 9-gene signature whose cDNA copy number was 





signature and 89 matched probes were found. The same 29 patient samples available in the array CGH 
data were selected from RNA data. The 9-gene signature and 29 sample RNA expression data versus 9-
gene signature and 29 sample CGH data was used to compute the correlation coefficient for each of the 
genes. After computing the correlation coefficient for each of the matching gene pairs, the genes with 
absolute value of correlation coefficient > 0.36 were considered to be significant (p < 0.05). The gene 
ITGB1 satisfied this condition and Table 3.29 shows the details. These genes might be helpful in 
identifying the regulators of gene expression. 
Table 3.29 Genes with correlation coefficient > 0.36 in the CGH versus RNA data. 











A_14_P128618 10 33274603 33274662 22571 ITGB1 0.4767 
A_14_P201824 10 33284494 33284553 22255 ITGB1 0.4321 
 
3.5.3 Genome wide correlation analysis on CGH and RNA data 
Our aim was to identify the cDNA copy numbers of the genes that were correlated with RNA expression 
data. The 29 tumor samples that were available in the CGH data were selected from the RNA data for the 
analysis. The genes in the CGH data were matched with the genes in the RNA data. Correlation 
coefficient was calculated for each of these matched gene pairs across the 29 tumor samples. The 
obtained correlation coefficients for each of the genes were converted to their absolute values, and all 
genes which with correlation coefficient values < 0.36 were removed. From the remaining set of genes, 3 
or more different consecutive genes were selected. Table 3.30 shows in detail the identified genes. The 







Table 3.30 Details of the genes identified by genome-wide correlation analysis. 
Chromosome 






Consecutive genes (count) 
1 11788695 11788743 144635 6 MTHFR (2)  CLCN6 (4) 
1 23864785 23864839 162971 5 LYPLA2 (1)  GALE (1)   MGCL (3) 
1 35990614 35990665 51144 6 EIF2C4 (1)  EIF2C1 (5) 
1 94617936 94617995 64611 10 ABCD3 (8)    F3 (2) 
1 1.13E+08 1.13E+08 79186 3 MOV10 (1)    RHOC (2) 
9 1.09E+08 1.09E+08 4486 5 ACTL7A (1)    IKBKAP (4) 
9 1.24E+08 1.24E+08 1752 6 NEK6 (1)    PSMB7 (5) 
9 1.37E+08 1.37E+08 81538 3 MGC14141 (2)     KIAA1984 (1) 
11 18374755 18374806 146020 3 LDHA (2)     LDHC (1) 
12 54789993 54790052 78424 3 PA2G4 (1)    RPL41 (2) 
14 75183472 75183531 75020 3 C14orf58 (1)     C14orf1 (2) 
14 95918447 95918506 126315 6 C14orf129 (1)     AK7 (5) 
16 23557994 23558053 42174 3 FLJ21816 (1)      MGC3248 (2) 
17 7232718 7232766 159975 3 TNK1 (2)    PLSCR3 (1) 
17 18160066 18160125 44369 5 SMCR8 (1)    SHMT1 (4) 
17 35087534 35087593 67698 8 PERLD1 (2)  ERBB2 (5) C17orf37 (1) 
20 17499809 17499868 161401 5 DSTN (4)     RRBP1 (1) 
20 32972022 32972071 118483 5 ACAS2 (2)      GSS (3) 
20 34697094 34697153 63618 8 SLA2 (2)      NDRG3 (6) 
20 43442415 43442474 29649 7 C20orf35 (5)      PIGT (2) 
20 60315571 60315630 19595 4 ADRM1 (2)     LAMA5 (2) 
21 26011625 26011684 70488 6 ATP5J (3)      GABPA (3) 








In this chapter, we identified a 9-gene signature to predict lymph node metastasis in colon cancer patients 
based on the microarray gene expression data. This was achieved by, firstly preprocessing the data to 
discard undifferentiated genes using the t-test, secondly replacing missing values with the k-nearest 
neighbors algorithm, and thirdly applying variable selection using random forests. In the next step, the 
genes without differential expression in lymph node negative versus positive tumors were removed in 
order to retain only the discriminator genes and obtained the 9-gene signature. The Kaplan-Meier plots of 
the 9-gene signature on Ried et al data (n=73) generated significant patient stratification into, low-risk 
and high-risk groups (log-rank tests, p < 0.05), with distinct relapse-free survival (RFS) and overall 
survival (OS). Out of the 73 patients in Ried et al data, 26 patients remained relapse-free for more than 5 
years and 10 patients experienced relapse within 5 years after surgery. In these patients, the Cox model 
had a sensitivity of 60.0% and a specificity of 92.3%. The 9-gene lymph node signature was cross 
validated on independent colon cancer data sets. The drug response to 5-FU (fluorouracil) on the NCI-60 
cell line data was predicted. Our results showed that it is feasible to predict the lymph node status of the 
patients with the 9-gene signature and it might be used for tailored treatments for patients in the high-risk 
group. Correlation analysis was done between the CGH and RNA data using the 14 gene signature and 
the gene ITGB1 was identified which exhibited strong relationship between the two groups. Genome 
wide correlation analysis was done to identify DNA copy numbers of the genes that were correlated with 











Prediction models for recurrence in colon cancer 
 
4.1 Introduction 
Recurrence or relapse is the reappearance of a tumor or the return of symptoms after treating for cancer. 
Postoperative treatment given to Duke’s stage B and Duke’s stage C colon cancer patients is highly 
debatable (24). It is uncertain whether adjuvant chemotherapy should be given to Duke’s stage B patients 
because not all the patients benefit from it. So, there is a need to identify patients at high-risk of 
recurrence who would develop relapse in the Duke’s B group so that they can be given aggressive 
treatment, and patients at low-risk of recurrence would be spared from the invasive treatment. Our study 
aims at identifying patients at low and high-risks of recurrence by building prognostic models for stage II 
(Duke’s stage B) and stage III (Duke’s stage C) colon cancer patients. 
The training set comprised of 36 patients (10 patients having recurrence within 5 years after 
surgery and 26 patients remaining relapse free for more than 5 years). The remaining 37 patients formed 
the testing set. The missing values in the gene expression data were replaced using the k-nearest 
neighbors algorithm with k=30. A combinatorial scheme was used to identify biomarkers predicting the 
recurrence. In the first step, variable selection using random forests was applied on the training set and a 
4-gene subset was obtained. In the second step, InfoGain feature selection technique was applied to 
further reduce the dimensionality by dropping lower ranked genes, and hence obtained the 3-gene 
signature. The same procedure was repeated again by replacing missing values in the preprocessed data 
with k-nearest neighbors algorithm (k=20) and obtained the 5-gene signature. 
The performance of these signatures was evaluated by cross validation on independent colon 
cancer data sets. The discriminatory powers of the identified gene signatures were evaluated by the time- 





risk groups. Prediction models were built with the 3-gene signature and the 5-gene signature using 
classifiers in Weka software to predict recurrence in patients from the testing set. These gene signatures 
were also cross validated on independent colon cancer datasets to evaluate their performance. 
The remainder of this chapter is organized as follows. Section 4.2 introduces our study design and 
describes the experiment in detail. Section 4.3 describes the validation results. Section 4.4 discusses the 
study design of 5-gene signature and describes the experiment in detail. Section 4.5 describes the 
validation results. Section 4.6 compares the 3-gene and 5-gene signatures, and Section 4.7 provides a 










































Figure 4.1 Block diagram of the study for 3-gene signature. 
Validation on Ried et al data, plotting Time-
dependent ROC and Kaplan Meier plots 
Building recurrence prediction model and cross validation 
on other colon cancer datasets  
3-gene signature 
Colon cancer data from Ried et al (n=73) 
Missing value replacement using knn 
algorithm on training set (k=30) 
Applying random forests using VarSelRF 
package using R software 
4-gene signature 
Using Infogain attribute selection in Weka to discard the 
gene with lowest rank (LOC114659-KIAA0563) 
Splitting data into training (n=36) and testing sets (n=37) 
 
Applying t-test on genes having > 5 missing values to determine differential gene 
expression in lymph node negative versus positive patients 
 
Selecting genes passing t-test and all other genes 






4.2.1 Experimental procedure  
 
Data Source The colon cancer microarray data from Ried et al. (13) contained 22,464 genes and 73 
patient samples, all of them treated for primary adenocarcinomas of the colon. Of these 33 tumor samples 
were stage II (lymph node negative) and 40 tumor samples were stage III (lymph node positive). 
Log Ratio Every spot on the microarray provides two intensity values each of them associated with a 
specific channel. Dividing one intensity by the other gives the expression ratio. We used log ratios as they 
are lot easier to work with than the regular ratios. The log ratio (532/635) was considered for this analysis. 
It is the log (base 2) transformation of the ratio of medians at wavelengths of 532nm and 635 nm. 
Data Preprocessing-t test We investigated whether the observed difference between the two groups 
(node positive versus negative) represents a real difference in the total study population from which the 
sample was drawn, or whether it just occurred by chance (due to sampling variation), by using t-test. The 
number of missing values for each gene was found and t-test was done on genes with more than 5 missing 
values to evaluate the difference in the proportions of missing values in node positive versus negative 
groups.  The genes passing the t-test (p < 0.05, two-sided) along with all other genes were selected for 
further processing. A total of 10,220 genes satisfied this condition. 
Training dataset The training dataset consisted of the patient samples having recurrence within 5 years 
after surgery, survival time ≥ 60 months selected based on the clinical data available for the dataset. The 
expression data of the 10,220 genes and 36 patients, constituted the training set. The remaining patients 
formed the testing set.   
Missing value replacement The training dataset contained missing values. They were replaced using the 
EMV 28
                                                     
28 http://cran.r-project.org/web/packages/EMV/index.html 
 package in R software with k=30. This technique estimates the missing values based on the k-





values to the one containing at least one missing value based on the Euclidian distance. Then the missing 
values are replaced by the average of the neighbors. 
Biomarker identification VarSelRF29
Table 4.1 The 3-gene signature for predicting colon cancer recurrence. 
 package in R was used in a series of steps on the training dataset 
to find the important features. The recurrence status was used as the class variable. In the first step, a 
forest with N trees was built and the features were ranked according to the importance of the variables. In 
the second step, 20% of the variables that were least important were removed and a new forest was 
constructed with K trees. This step was repeated till there were two genes left. In the experiment, a value 
of N = 2000 and K =1000 were considered, because a large number of trees in the initial forests is likely 
to produce stable importance measures (23). After fitting all forests, the OOB error rates from all the 
fitted random forests were examined and a set of 4 genes leading to the smallest error rate were selected. 
InfoGain attribute selection technique was applied to drop the least ranked gene, LOC114659--KIAA0563, 
giving us the 3-gene signature. Table 4.1 shows the 3-gene signature. 
GENE NAME  ID 
LRRC14-leucine rich repeat containing H200014103 
E2F2-E2F transcription factor 2 (E2F2) H200012309 

























4.3.1 Building prediction model using Weka 
 
The training set consisted of expression data of the 3-gene signature in 36 patients (10 patients having 
recurrence within 5 years after surgery and 26 patients having survival time more than 5 years without 
recurrence). The remaining patients formed the testing set. Weka software was used for 10 fold cross 
validation on the training dataset. Different classification schemes in Weka were applied to this dataset to 
find the best scheme. Table 4.2 shows the top five classifiers including LWL, AD Tree, Multialyer 
perceptron, IB1, and Logistic regression based on their prediction accuracies. LWL classifier performed 
better than the other classifiers. It had a sensitivity of 80.00%, a specificity of 96.20%, and an overall 
accuracy of 91.66%. Table 4.3 shows the confusion matrix for LWL classifier. The difference in overall 
accuracy between LWL and other classifiers was not statistically significant due to the small sample size. 
The LWL classifier model was saved and used to predict class (recurrence/no recurrence) for patients in 
the testing set. Table 4.4 shows the predicted class for patients in the testing set using the LWL model and 
compares it with the class predictions obtained from the Cox model. 
Table 4.2 Comparison of accuracies obtained from different classifiers for predicting recurrence 
using the 3-gene signature. The improved overall accuracy of the prediction with the LWL 
classifier compared with other methods was assessed by significance testing (N = 36).  










LWL 80.00 96.20 88.10 91.66  
AD Tree 60.00 96.20 78.10 83.33 < 0.14 
Multilayer perceptron 60.00 92.30 76.15 83.33 < 0.14 
IB1 40.00 92.30 66.15 77.77 < 0.06 
Logistic regression 30.00 96.20 63.10 77.77 < 0.06 
 
Table 4.3 Confusion matrix obtained from the LWL classifier for predicting recurrence using the 3-
gene signature. 
Actual/Predicted a (recurrence) b (no recurrence) 
a (recurrence) 8 2 














Cox model Match 
1 CC-P1 No recurrence No recurrence Y 
2 CC-P2 No recurrence No recurrence Y 
3 CC-P4 No recurrence No recurrence Y 
4 CC-P7 Recurrence Recurrence Y 
5 CC-P8 No recurrence No recurrence Y 
6 CC-P10 No recurrence No recurrence Y 
7 CC-P13 No recurrence No recurrence Y 
8 CC-P18 Recurrence Recurrence Y 
9 CC-P20 No recurrence No recurrence Y 
10 CC-P21 No recurrence No recurrence Y 
11 CC-P22 No recurrence No recurrence Y 
12 CC-P23 No recurrence No recurrence Y 
13 CC-P25 No recurrence No recurrence Y 
14 CC-P28 No recurrence No recurrence Y 
15 CC-P29 Recurrence Recurrence Y 
16 CC-P31    Recurrence No recurrence - 
17 CC-P34 No recurrence No recurrence Y 
18 CC-P35 No recurrence Recurrence - 
19 CC-P37 No recurrence No recurrence Y 
20 CC-P38 No recurrence Recurrence - 
21 CC-P40 No recurrence No recurrence Y 
22 CC-P42 No recurrence No recurrence Y 
23 CC-P44 No recurrence No recurrence Y 
24 CC-P46 No recurrence Recurrence - 
25 CC-P47 No recurrence No recurrence Y 
26 CC-P48 No recurrence No recurrence Y 
27 CC-P50 Recurrence Recurrence Y 
28 CC-P51 Recurrence Recurrence Y 
29 CC-P55 No recurrence Recurrence - 
30 CC-P56 No recurrence Recurrence - 
31 CC-P60 Recurrence No recurrence - 
32 CC-P62 No recurrence No recurrence Y 
33 CC-P66 No recurrence No recurrence Y 
34 CC-P68 Recurrence Recurrence Y 
35 CC-P70 Recurrence No recurrence - 
36 CC-P71 Recurrence No recurrence - 






4.3.2 Plotting Kaplan-Meier curves based on the patient subgroups obtained from 
LWL prediction model on data from Ried et al (n=73) using the 3-gene signature 
 
The LWL recurrence prediction model discussed in the previous section generated two subgroups of 
patients, no recurrence and recurrence, on the training and testing data sets. Kaplan-Meier curves were 
plotted based on the expression data of 3-gene signature in the 73 patient samples (Ried et al data) and the 
patient subgroups obtained from LWL prediction model. The Kaplan-Meier plots generated significant 
patient stratification into no recurrence and recurrence groups (p < 0.05, n=73, log-rank tests), with 
distinct relapse-free survival. Figure 4.2 shows the survival probabilities for each of the patient subgroups 
for relapse-free survival. 
 
 
Figure 4.2 Kaplan-Meier plots on data from Ried et al (n=73) for relapse-free survival using the 3-
gene signature based on the patient subgroups obtained from LWL recurrence prediction model. 
 
4.3.3 Time-dependent ROC analyses data from Ried et al (n=73) 
 
To explore whether the 3-gene recurrence signature could predict patient disease-free survival and overall 
survival, the survival and status information along with the expression data of the 3 genes were used for 
getting the time-dependent ROC curves. The accuracy of 5-year relapse-free survival prediction using 





                                  
 
Figure 4.3 Time-dependent ROC plots on data from Ried et al (n=73) for relapse-free survival and 
overall survival using the 3-gene signature. 
 
4.3.4 Kaplan-Meier analyses on data from Ried et al (n=73) 
 
The Cox model based on the expression of the 3-gene signature was used to get recurrence risk scores for 
all the 73 patient samples. The choices for choosing a cut-off value for patient stratification are the peak 
value from histogram, mean risk score or median risk score. In this analysis, the peak value from 
histogram was chosen as cut-off as it resulted in best patient stratification. Cut-off values of 2.0 and 1.0 
were chosen for relapse-free survival and overall survival, respectively. The pamr package in R was used 
to plot the relapse-free survival probability of low-risk and high-risk groups. The low-risk and high-risk 
groups had distinct relapse-free survival (p = 1e-04, n=73, log-rank tests). The low-risk and high-risk 





                             
Figure 4.4 Histograms of risk scores obtained from Cox model for relapse-free survival and overall 
survival using the 3-gene signature 
 
                                                 
 
Figure 4.5 Kaplan-Meier plots on data from Ried et al (n=73) for relapse-free survival and overall 
survival using the 3-gene signature 
 
Out of the 73 patients in the colon cancer data from Ried et al, 26 patients remained relapse-free for more 
than 5 years and 10 patients had recurrence within 5 years after surgery. To test the performance of the 3-
gene signature, the subgroups obtained for the above group of 36 patients from the Cox model were 
compared with their actual clinical outcomes. Table 4.5 shows the different parameters obtained from 





4.6 and 4.7, show the comparison of predicted clinical outcome for patients with their actual follow-up 
information, for relapse-free survival and overall survival, respectively. The Cox model had a sensitivity 
of 80.0%, a specificity of 96.1%, and an overall accuracy of 91.7%, for predicting relapse-free survival. 
In predicting overall survival, it had a sensitivity of 40.0%, a specificity of 95.9%, and an overall 
accuracy of 70.4%.  
Table 4.5 Different parameters obtained from Cox model using the 3-gene signature for relapse-
free survival and overall survival 



















LRRC14 0.449 1.647 0.529 0.943 0.350 0.213 1.238 0.376 0.568 0.570 
E2F2 -1.500 0.223 0.586 -2.561 0.010 -0.666 0.513 0.335 -1.988 0.047 
SLC25A5 0.375 1.455 0.216 1.738 0.082 0.081 1.085 0.179 0.455 0.650 
 
Table 4.6 Comparison of the sub groups predicted from the Cox model using the 3-gene signature 
with the actual subgroups for relapse-free survival 
 
 Recurrence No recurrence Sensitivity (%) Specificity (%) Overall accuracy (%) 
Recurrence 8 2 80.0 96.1 91.7 No recurrence 1 25 
 
Table 4.7 Comparison of the sub groups predicted from the Cox model using the 3-gene signature 
with the actual subgroups for overall survival 
 Death Alive Sensitivity (%) Specificity (%) Overall accuracy (%) 
Death 8 12 40.0 95.9 70.4 Alive 1 23 
 
The Cox model was used for stratifying all the 73 patient samples in Ried et al data into low-risk and 
high-risk groups, based on the 3-gene signature. Out of the 73 patients, a total of 37 patients had no 
recurrence with survival times less than 5 years. Twenty-nine patients had overall survival times less than 
5 years without any event (death). The relapse outcome for the 37 patients and the overall survival 
outcome for the 29 patients is currently unknown. Table 4.8 shows the prospective prognostic predictions 





The follow-up information for these patients is being collected. When it becomes available in the future, 

























Number Patient ID 
Predicted group by 
Cox model (RFS) Patient ID 
Predicted group by 
Cox model (OS) 
1 CC-P1 Low Risk CC-P1 Low Risk 
2 CC-P2 Low Risk CC-P4 Low Risk 
3 CC-P4 Low Risk CC-P7 Low Risk 
4 CC-P7 High Risk CC-P8 Low Risk 
5 CC-P8 Low Risk CC-P9 Low Risk 
6 CC-P10 Low Risk CC-P11 Low Risk 
7 CC-P13 Low Risk CC-P13 Low Risk 
8 CC-P18 High Risk CC-P16 Low Risk 
9 CC-P20 Low Risk CC-P18 High Risk 
10 CC-P21 Low Risk CC-P20 Low Risk 
11 CC-P22 Low Risk CC-P21 Low Risk 
12 CC-P23 Low Risk CC-P22 Low Risk 
13 CC-P25 Low Risk CC-P25 Low Risk 
14 CC-P28 Low Risk CC-P28 Low Risk 
15 CC-P29 High Risk CC-P31 Low Risk 
16 CC-P31 Low Risk CC-P35 High Risk 
17 CC-P34 Low Risk CC-P36 High Risk 
18 CC-P35 High Risk CC-P37 Low Risk 
19 CC-P37 Low Risk CC-P38 Low Risk 
20 CC-P38 High Risk CC-P40 Low Risk 
21 CC-P40 Low Risk CC-P48 Low Risk 
22 CC-P42 Low Risk CC-P50 High Risk 
         23 CC-P44 Low Risk CC-P51 High Risk 
24 CC-P46 High Risk CC-P60 Low Risk 
25 CC-P47 Low Risk CC-P62 Low Risk 
26 CC-P48 Low Risk CC-P66 Low Risk 
27 CC-P50 High Risk CC-P71 Low Risk 
28 CC-P51 High Risk CC-P72 Low Risk 
29 CC-P55 High Risk CC-P73 High Risk 
30 CC-P56 High Risk   
31 CC-P60 Low Risk   
32 CC-P62 Low Risk   
33 CC-P66 Low Risk   
34 CC-P68 High Risk   
35 CC-P70 Low Risk   
36 CC-P71 Low Risk   





4.3.5 Independence of 3-gene recurrence signature of tumor stage 
 
Improved prediction of recurrence can profoundly affect clinical decisions. However, following the 
current clinical guidelines, few of the lymph node-negative patients (stage II) are offered adjuvant 
chemotherapy. Because 25% to 40% of the patients would develop tumor relapse, the prognosis signature 
can be a powerful tool to select the patients who are at high-risk and ensure that they receive adjuvant 
treatment. This part of the study was focused on verifying if the recurrence predictions obtained on Ried 
et al data were statistically significant when validated separately in Stage II and Stage III patients. It was 
seen that the 3-gene signature could stratify the patients into low-risk and high-risk groups in Stage II and 
Stage III samples individually with distinct relapse-free survival. The patient subgroups were obtained 
based on the Cox model. The patients belonging to the low-risk group had higher survival probabilities 
than those belonging to the high-risk group. Based on the predictions from LWL model using the 3-gene 
signature, Kaplan-Meier plots were plotted in Stage II and Stage III samples separately. But the patient 
stratification was not statistically significant and the results were not reported. So it can be said that Cox 
model is the best model for predicting recurrence using the 3-gene signature. These results confirm that 
the 3-gene recurrence signature might be applicable to prognostic categorization for the clinical 
management of colon cancer. 
                             
Figure 4.6 The 3-gene signature stratifies patients in Stage II tumors and Stage III tumors into 





4.3.6 External validation of the 3-gene signature on other colon cancer data 
 
This part of the study sought to explore the extent to which the 3-gene signature could be used for 
prediction of lymph node status, recurrence, and drug response in publicly available independent datasets. 
More than 50 classifiers available in Weka software were tested using a leave-one-out cross validation 
technique on each of the independent datasets to find a suitable classification scheme for validation. Due 
to the different number of attributes (matching genes), sample sizes and prediction variables one specific 
scheme could not be used for validation on all the datasets. Different classifiers had to be employed on 
the validation datasets to get fair prediction accuracy. As far as possible the same set of classifiers were 
presented in the comparison tables of validation datasets to provide a fair evaluation of the performance. 
The exact same set of classifiers could not be compared over all the validation datasets due to poor 
performances of classifiers on some datasets and good performances on other datasets. The following 
sections discuss the validation results and comparisons of various classifiers on the independent datasets 
in detail. 
4.3.6.1 Predicting lymph node status by leave-one-out cross validation on data from 
Koinuma et al. (n=17) (PMID 16247484) 
 
The data from Koinuma et al (Affymetrix HG U133 A platform) consisted of 20 patient samples of which 
3 patients were Duke’s stage D. The Duke’s stage D patients were not considered for validation. The 
search for matching genes with the 3-gene signature was done using the Affymetrix ids. There were 3 
matching genes (Table 4.9). The data used for validation consisted of the expression of these 3 genes in 
the 17 patient samples. Weka software was used for validation and lymph node status (positive/negative) 
was predicted. Different classification schemes including Multilayer perceptron, Decision stump, Logistic 
regression, JRip, and Adaboost M1 were applied to this dataset to find the best scheme. Table 4.10 shows 
the comparison between Multilayer perceptron and some of the classifiers used for validation on other 
datasets. Multilayer perceptron classifier performed better than the other classifiers. It had a sensitivity of 





matrix for Multilayer perceptron classifier. The difference in overall accuracy between Multilayer 
perceptron and other classifiers was not statistically significant due to the small sample size. 
Table 4.9 Matching genes in Koinuma et al data 
GENE NAME  ID 
LRRC14-leucine rich repeat containing H200014103 
E2F2-E2F transcription factor 2 (E2F2) H200012309 
SLC25A5-solute carrier family 25 H200006643 
 
Table 4.10 Comparison of accuracies obtained from different classifiers for predicting lymph node 
status using the 3-gene signature. The improved overall accuracy of the prediction with the 
Multilayer perceptron classifier compared with other methods was assessed by significance testing 
(N = 17). 










Multilayer perceptron 71.40 90.00 80.70 82.35  
Decision stump 42.90 100.00 71.45 76.47 < 0.33 
Logistic regression 57.10 80.00 68.55 70.58 < 0.21 
JRip 14.30 100.00 57.15 64.70 < 0.13 
Adaboost M1 28.60 80.00 54.30 58.82 < 0.06 
 
Table 4.11 Confusion matrix obtained from the Multilayer perceptron classifier for predicting 
lymph node status using the 3-gene signature. 
Actual/Predicted a (positive) b (negative) 
a (positive) 5 2 
b (negative) 1 9 
  
4.3.6.2 Predicting recurrence by leave-one-out cross validation on data from Barrier et al. 
(n=18) (PMID 16091735) 
 
The data from Barrier et al (PMID 16091735) consisted of 22,283 genes and 18 patient samples. The 
search for matching genes with the 3-gene signature was done using the Affymetrix ids. There were 3 
matching genes (Table 4.12). The data used for validation consisted of the expression of these 3 genes in 
the 18 patient samples. Weka software was used for validation and recurrence (yes/no) was predicted. 





and IB1 were applied to this dataset to find the best scheme. Table 4.13 shows the comparison between 
Threshold selector and some of the classifiers used for validation on other datasets. Threshold selector 
classifier performed better than the other classifiers. It had a sensitivity of 88.90%, a specificity of 
77.80%, and an overall accuracy of 83.33%. Table 4.14 shows the confusion matrix for Threshold 
selector classifier. The difference in overall accuracy between Threshold selector and other classifiers was 
not statistically significant due to the small sample size. 
Table 4.12 Matching genes in Barrier et al data. 
GENE NAME  ID 
LRRC14-leucine rich repeat containing H200014103 
E2F2-E2F transcription factor 2 (E2F2) H200012309 
SLC25A5-solute carrier family 25 H200006643 
 
Table 4.13 Comparison of accuracies obtained from different classifiers for predicting recurrence 
using the 3-gene signature. The improved overall accuracy of the prediction with the Threshold 
selector classifier compared with other methods was assessed by significance testing (N = 18). 










Threshold selector 88.90 77.80 83.35 83.33  
AdaboostM1 77.80 77.80 77.80 77.77 < 0.34 
LWL 77.80 77.80 77.80 77.77 < 0.34 
Multilayer perceptron 77.80 66.70 72.25 72.22 < 0.22 
IB1 66.70 66.70 66.70 66.66 < 0.13 
 
Table 4.14 Confusion matrix obtained from the Threshold selector classifier for predicting 
recurrence using the 3-gene signature 
Actual/Predicted a (recurrence) b (no recurrence) 
a (recurrence) 8 1 
b (no recurrence) 2 7 
 
4.3.6.3 Predicting recurrence by leave-one-out cross validation on data from Barrier et al. 
(n=50) (PMID 16966692) 
 
The data from Barrier et al (PMID 16966692) consisted of 22,283 genes and 50 patient samples. The 





matching genes (Table 4.15). The data used for validation consisted of the expression of these 3 genes in 
the 50 patient samples. Weka software was used for validation and recurrence (yes/no) was predicted. 
Different classification schemes including IB1, LWL, Multilayer perceptron, Random committee, and 
AdaboostM1 were applied to this dataset to find the best scheme. Table 4.16 shows the comparison 
between IB1 and some of the classifiers used for validation on other datasets. IB1 classifier performed 
better than the other classifiers. It had a sensitivity of 76.00%, a specificity of 80.00%, and an overall 
accuracy of 78.00%. Table 4.17 shows the confusion matrix for IB1 classifier. The difference in overall 
accuracy between IB1 and other classifiers was not statistically significant due to the small sample size. 
Table 4.15 Matching genes in Barrier et al data. 
GENE NAME  ID 
LRRC14-leucine rich repeat containing H200014103 
E2F2-E2F transcription factor 2 (E2F2) H200012309 
SLC25A5-solute carrier family 25 H200006643 
 
Table 4.16 Comparison of accuracies obtained from different classifiers for predicting recurrence 
using the 3-gene signature. The improved overall accuracy of the prediction with the IB1 classifier 
compared with other methods was assessed by significance testing (N = 50). 










IB1 76.00 80.00 78.00 78.00  
LWL 68.00 84.00 76.00 76.00 < 0.41 
Multilayer perceptron 80.00 68.00 74.00 74.00 < 0.32 
Random committee 68.00 72.00 70.00 70.00 < 0.18 
AdaboostM1 56.00 80.00 68.00 68.00 < 0.12 
 
Table 4.17 Confusion matrix obtained from the IB1 classifier for predicting recurrence using the 3-
gene signature. 
Actual/Predicted a (no recurrence) b (recurrence) 
a (no recurrence) 20 5 








4.3.6.4 Predicting the response of cell lines in NCI-60 (U133A GCRMA) data (n=34) by 
leave-one-out cross validation on data 
 
This dataset30
Table 4.18 Matching genes in NCI-60 U133A data. 
 consisted of 21,225 genes and 60 cell lines (41). Our focus was on the sensitive and 
resistant cell lines, so cell lines with intermediate response were not considered for validation. A total of 
34 cell lines (17 sensitive and the other 17 resistant to the drug 5-FU) were used in validation. The search 
for matching genes was done using the gene symbols. There were 3 matching genes (Table 4.18). The 
data used for validation consisted of the expression of these 3 genes in the 34 cell lines. Weka software 
was used for validation and the response (sensitive/resistant) for the drug 5-FU (fluorouracil) was 
predicted. Different classification schemes including Threshold selector, Multilayer perceptron, IB1, 
LWL, and Logistic regression were applied to this dataset to find the best scheme. Table 4.19 shows the 
comparison between Threshold selector and some of the classifiers used for validation on other datasets. 
Threshold selector classifier performed better than the other classifiers. It had a sensitivity of 94.10%, a 
specificity of 88.20%, and an overall accuracy of 91.17%. Table 4.20 shows the confusion matrix for 
Threshold selector classifier. The difference in overall accuracy between Threshold selector and 
Multilayer perceptron (p < 0.01), IB1 (p < 0.01), LWL (p < 0.01), Logistic regression (p < 0.01) was 
statistically significant. 
GENE NAME  ID 
LRRC14-leucine rich repeat containing H200014103 
E2F2-E2F transcription factor 2 (E2F2) H200012309 












Table 4.19 Comparison of accuracies obtained from different classifiers for predicting drug 
response using the 3-gene signature. The improved overall accuracy of the prediction with the 
Threshold selector classifier compared with other methods was assessed by significance testing (N = 
34). 










Threshold selector 94.10 88.20 91.15 91.17  
Multilayer perceptron 70.60 41.20 55.90 55.88 < 0.01 
IB1 64.70 47.10 55.90 55.88 < 0.01 
LWL 82.40 29.40 55.90 55.88 < 0.01 
Logistic regression 35.30 58.80 47.05 47.05 < 0.01 
 
Table 4.20 Confusion matrix obtained from the Threshold selector classifier for predicting drug 
response using the 3-gene signature. 
Actual/Predicted a (sensitive) b (resistant) 
a (sensitive) 16 1 
b (resistant) 2 15 
 
4.3.6.5 Predicting the response of cell lines in NCI-60 (U133B GCRMA) data (n=34) by 
leave-one-out cross validation on data 
 
This dataset31
                                                     
31 http://discover.nci.nih.gov/cellminer/loadDownload.do 
 consisted of 17910 genes and 60 cell lines (41). Our focus was on the sensitive and resistant 
cell lines, so cell lines with intermediate response were not considered for validation. A total of 34 cell 
lines (17 sensitive and the other 17 resistant to the drug 5-FU) were used in validation. The search for 
matching genes was done using the gene symbols. There was 1 matching gene (Table 4.21). The data 
used for validation consisted of the expression of this gene in the 34 cell lines. Weka software was used 
for validation and the response (sensitive/resistant) for the drug 5-FU (fluorouracil) was predicted. 
Different classification schemes including Threshold selector, IB1, Multilayer perceptron, LWL, and 
Bagging were applied to this dataset to find the best scheme. Table 4.22 shows the comparison between 
Threshold selector and some of the classifiers used for validation on other datasets. Threshold selector 





88.23%, and an overall accuracy of 88.23%. Table 4.23 shows the confusion matrix for Threshold 
selector classifier. The difference in overall accuracy between Threshold selector and IB1 (p < 0.01), 
Multilayer perceptron (p < 0.01), LWL (p < 0.01), Bagging (p < 0.01) was statistically significant. 
Table 4.21 Matching genes in NCI-60 U133B data. 
GENE NAME  ID 
E2F2-E2F transcription factor 2 (E2F2) H200012309 
 
Table 4.22 Comparison of accuracies obtained from different classifiers for predicting drug 
response using the 3-gene signature. The improved overall accuracy of the prediction with the 
Threshold selector classifier compared with other methods was assessed by significance testing (N = 
34). 










Threshold selector 88.23 88.23 88.23 88.23  
IB1 47.10 52.90 50.00 50.00 < 0.01 
Multilayer perceptron 11.80 82.40 47.10 47.05 < 0.01 
LWL 29.40 58.80 44.10 44.11 < 0.01 
Bagging 35.30 47.10 41.20 41.17 < 0.01 
 
Table 4.23 Confusion matrix obtained from the Threshold selector classifier for predicting drug 
response using the 3-gene signature. 
Actual/Predicted a (sensitive) b (resistant) 
a (sensitive) 15 2 













4.3.7 Summary of validation results of 3-gene signature 
 
Table 4.24 shows the details of different validation datasets, predicted variables, classifiers used and 
different accuracies obtained using the 3-gene signature. For each dataset the classifier with the highest 
overall accuracy was reported.  
Table 4.24 Summary of validation results of 3-gene signature on Ried et al data, independent colon 
cancer datasets and NCI 60 data. 











Ried et al training set 
(n=36)  
PMID 17210682 
LWL Recurrence 80.00 96.20 88.10 91.66 




model Recurrence 80.00 96.20 88.10 91.66 






node status 71.40 90.00 80.70 82.35 




selector Recurrence 88.90 77.80 83.35 83.33 
Barrier et al 
(n=50) 
PMID 16966692 
IB1 Recurrence 76.00 80.00 78.00 78.00 







94.10 88.20 91.15 91.17 












































Figure 4.7 Block diagram of the study for 5-gene signature 
Validation on Ried et al data, plotting Time-
dependent ROC and Kaplan Meier plots 
Building recurrence prediction model and cross validation 
on other colon cancer datasets 
5-gene signature 
Colon cancer data from Ried et al (n=73) 
Missing value replacement using knn 
algorithm on training set (k=20) 
Applying random forests using VarSelRF 
package using R software 
8-gene signature 
Using Infogain attribute selection in Weka to rank the 
genes and discarding the 3 genes with lowest ranks 
 
 
Splitting data into training (n=36) and testing sets (n=37) 
 
Applying t-test on genes having > 5 missing values to determine differential gene 
expression in lymph node negative versus positive patients 
 
Selecting genes passing t-test and all other genes 






4.4.1 Experimental procedure 
 
Data Source The colon cancer microarray data from Ried et al. (13) contained 22,464 genes and 73 
patient samples, all of them treated for primary adenocarcinomas of the colon. Of these 33 tumor samples 
were stage II (lymph node negative) and 40 tumor samples were stage III (lymph node positive). 
Log Ratio Every spot on the microarray provides two intensity values each of them associated with a 
specific channel. Dividing one intensity by the other gives the expression ratio. We used log ratios as they 
are lot easier to work with than regular ratios. The log ratio (532/635) was considered for this analysis 
which is log (base 2) transformation of the ratio of medians at wavelengths of 532nm and 635 nm.  
Data Preprocessing - t test We investigated whether the observed difference between the two groups 
(node positive versus negative) represents a real difference in the total study population from which the 
sample was drawn, or whether it just occurred by chance (due to sampling variation), by using t-test.  The 
number of missing values for each gene was found and t-test was done on genes with more than 5 missing 
values to evaluate the difference in the proportions of missing values in node positive versus negative 
groups. The genes passing the t-test (p < 0.05, two-sided) were included along with all genes having less 
than 5 missing values for further processing. A total of 10,220 genes satisfied this condition. 
Training dataset The training dataset consisted of the patient samples with recurrence, survival time ≥ 60 
months selected based on the clinical data available for the dataset. The expression data of the 10,220 
genes and 36 patients, constituted the training set. The remaining patients formed the testing set. 
Missing value replacement The training dataset contained missing values. They were replaced using the 
EMV 32
                                                     
32 http://cran.r-project.org/web/packages/EMV/index.html 
 package in R software with k=20. This technique estimates the missing values based on the k 





values to the one containing at least one missing value, based on the Euclidian distance. Then the missing 
values are replaced by the average of the neighbors. 
Biomarker identification VarSelRF33
Table 4.25 The 5-gene signature for predicting colon cancer recurrence. 
 package in R was used in a series of steps on the training dataset 
to find the important features. The recurrence status was used as the class variable. In the first step, a 
forest with N trees was built and the features were ranked according to the importance of the variables. In 
the second step, 20% of the variables that were least important were removed and a new forest was 
constructed with K trees. This step was repeated till there were two genes left. In the experiment, a value 
of N = 2000 and K =1000 were considered, because a large number of trees in the initial forests is likely 
to produce stable importance measures (23). After fitting all forests, the OOB error rates from all the 
fitted random forests were examined and a set of 8 genes leading to the smallest error rate were selected. 
The InfoGain attribute selection technique was used to drop three least ranked genes (LOC114659--
KIAA0563, cDNA DKFZp564O1172, and NET1) and obtained the 5-gene signature. Table 4.25 shows the 
5-gene signature. 
GENE NAME  ID 
TPD52L2-tumor protein D52-like2 H200013992 
CDNA FLJ44020 fis, clone TESTI4026295 H200020685 
ZNF187-zinc finger protein 187 (ZNF187) H200015602 
HSPA14-heat shock 70kDa protein 14 H200018991 
















4.5.1 Building prediction model using Weka 
 
The training set consisted of expression data of the 5-gene signature in 36 patients (10 patients having 
recurrence within 5 years after surgery and 26 patients having survival time more than 5 years without 
recurrence). The remaining patients formed the testing set. 10-fold cross validation was used on the 
training dataset. Different classification schemes in Weka were applied on the training set to find the best 
scheme. Table 4.26 shows the top five classifiers including Random Tree, KStar, AD Tree, IB1, and 
Multilayer perceptron based on their prediction accuracies. Random Tree classifier performed better than 
the other classifiers. It had a sensitivity of 70.00%, a specificity of 88.46% and an overall accuracy of 
83.33%. Table 4.27 shows the confusion matrix for Random Tree classifier. The difference in overall 
accuracy between Random Tree and other classifiers was not statistically significant due to the small 
sample size. The Random Tree classifier model was saved and used to predict class (recurrence/no 
recurrence) for patients in the testing set. Table 4.28 shows the predicted class for patients in the testing 
set using the Random Tree prediction model and compares it with the class predictions obtained from the 
Cox model. 
Table 4.26 Comparison of accuracies obtained from different classifiers for predicting recurrence 
using the 5-gene signature. The improved overall accuracy of the prediction with the Random Tree 
classifier compared with other methods was assessed by significance testing (N = 36). 










Random Tree 70.00 88.46 79.23 83.33  
KStar 40.00 92.30 66.15 77.77 < 0.28 
AD Tree 50.00 84.60 67.30 75.00 < 0.19 
IB1 30.00 88.50 59.25 72.22 < 0.13 









Table 4.27 Confusion matrix obtained from the Random Tree classifier for predicting recurrence 
using the 5-gene signature. 
Actual/Predicted a (no recurrence) b (recurrence) 
a (no recurrence) 23 3 






































Cox model Match 
1 CC-P1 No recurrence No recurrence Y 
2 CC-P2 No recurrence Recurrence - 
3 CC-P4 No recurrence No recurrence Y 
4 CC-P7 No recurrence No recurrence Y 
5 CC-P8 No recurrence Recurrence - 
6 CC-P10 No recurrence No recurrence Y 
7 CC-P13 No recurrence No recurrence Y 
8 CC-P18 No recurrence Recurrence - 
9 CC-P20 No recurrence Recurrence - 
10 CC-P21 No recurrence No recurrence Y 
11 CC-P22 Recurrence Recurrence Y 
12 CC-P23 No recurrence No recurrence Y 
13 CC-P25 No recurrence No recurrence Y 
14 CC-P28 No recurrence Recurrence - 
15 CC-P29 No recurrence Recurrence - 
16 CC-P31 Recurrence No recurrence - 
17 CC-P34 No recurrence Recurrence - 
18 CC-P35 No recurrence Recurrence - 
19 CC-P37 No recurrence No recurrence Y 
20 CC-P38 No recurrence No recurrence Y 
21 CC-P40 No recurrence No recurrence Y 
22 CC-P42 No recurrence No recurrence Y 
23 CC-P44 No recurrence No recurrence Y 
24 CC-P46 No recurrence No recurrence Y 
25 CC-P47 No recurrence No recurrence Y 
26 CC-P48 No recurrence No recurrence Y 
27 CC-P50 No recurrence No recurrence Y 
28 CC-P51 Recurrence No recurrence - 
29 CC-P55 No recurrence No recurrence Y 
30 CC-P56 No recurrence No recurrence Y 
31 CC-P60 No recurrence No recurrence Y 
32 CC-P62 No recurrence No recurrence Y 
33 CC-P66 No recurrence No recurrence Y 
34 CC-P68 No recurrence No recurrence Y 
35 CC-P70 No recurrence Recurrence - 
36 CC-P71 Recurrence Recurrence Y 






4.5.2 Plotting Kaplan-Meier curves based on the patient subgroups obtained from 
Random Tree prediction model on data from Ried et al (n=73) using the 5-gene 
signature 
 
The Random Tree recurrence prediction model discussed in the previous section generated two subgroups 
of patients, recurrence and no recurrence on the training and testing data sets. Kaplan-Meier curves were 
plotted based on the expression data of 5-gene signature in the 73 patient samples (Ried et al) and the 
patient subgroups obtained from Random Tree prediction model. The Kaplan-Meier plots generated 
significant patient stratification into no recurrence and recurrence groups (p < 0.05, n=73, log-rank tests), 
with distinct relapse-free survival. Figure 4.8 shows the survival probabilities for each of the patient 
subgroups for relapse-free survival. 
 
Figure 4.8 Kaplan-Meier plots on data from Ried et al (n=73) for relapse-free survival using the 5-
gene signature, based on patient subgroups obtained from Random Tree recurrence prediction 
model. 
 
4.5.3 Time-dependent ROC analyses on data from Ried et al (n=73) 
 
To explore whether the 5-gene recurrence signature could predict patient disease-free survival and overall 
survival, the survival and status information along with the expression data of the 5 genes were used for 
getting the time-dependent ROC curves. The accuracy of 5-year relapse-free survival prediction using 





                                  
 
Figure 4.9 Time-dependent ROC plots on data from Ried et al (n=73) for relapse-free survival and 
overall survival using the 5-gene signature. 
 
4.5.4 Kaplan-Meier analyses on data from Ried et al (n=73) 
 
The Cox model based on the expression of the 5-gene signature was used to get recurrence risk scores for 
all 73 patient samples. The choices for choosing a cut-off value for patient stratification are the peak value 
from histogram, mean risk score or median risk score. In this analysis, the peak value from histogram was 
chosen as cut-off as it resulted in best patient stratification. Cut-off values of 0.25 and -0.5 were chosen 
for relapse-free survival and overall survival, respectively. The pamr package in R was used to plot the 
relapse-free survival probability of low-risk and high-risk groups. The low-risk and high-risk groups had 
distinct relapse-free survival (p = 0.01, n=73, log-rank tests). The low-risk and high-risk groups had 





                           
Figure 4.10 Histograms of risk scores obtained from Cox model for relapse-free survival and 
overall survival using the 5-gene signature. 
 
                                                                
 
Figure 4.11 Kaplan-Meier plots on data from Ried et al (n=73) for relapse-free survival and overall 
survival using the 5-gene signature. 
 
Out of the 73 patients in the colon cancer data from Ried et al, 26 patients remained relapse-free for more 
than 5 years and 10 patients had recurrence within 5 years after surgery. To test the performance of the 5-
gene signature the subgroups obtained for the above group of 36 patients from the Cox model were 
compared with their actual clinical outcomes. Table 4.29 shows the different parameters obtained from 
the Cox model using the 5-gene signature, for relapse-free survival and overall survival, respectively. 





follow-up information, for relapse-free survival and overall survival, respectively. The Cox model had a 
sensitivity of 70.0%, a specificity of 80.8%, and an overall accuracy of 77.8%, for predicting relapse-free 
survival. In predicting overall survival, it had a sensitivity of 30.0%, a specificity of 91.7%, and an overall 
accuracy of 63.6%.  
Table 4.29 Different parameters obtained from Cox model using the 5-gene signature for relapse-
free survival and overall survival. 
Relapse-free survival Overall survival 













TPD52L2 1.0024 2.725 0.571 1.7548 0.079 0.519 1.680 0.325 1.596 0.11 
CDNAFLJ44020 0.6445 1.905 0.483 1.3351 0.180 0.389 1.476 0.278 1.398 0.16 
ZNF187 -0.0248 0.975 0.266 -0.0935 0.930 0.081 1.084 0.075 1.079 0.28 
HSPA14 0.0749 1.078 0.344 0.2181 0.830 -0.159 0.853 0.214 -0.742 0.46 
SLC25A5 -0.1238 0.884 0.349 -0.3547 0.720 -0.092 0.912 0.249 -0.368 0.71 
 
Table 4.30 Comparison of the sub groups predicted from the Cox model using the 5-gene signature 
with the actual subgroups for relapse-free survival. 
 Recurrence No recurrence Sensitivity (%) Specificity (%) Overall Accuracy (%) 
Recurrence 7 3 70.0 80.8 77.8 No recurrence 5 21 
 
Table 4.31 Comparison of the sub groups predicted from the Cox model using the 5-gene signature 
with the actual subgroups for overall survival. 
 Death Alive Sensitivity (%) Specificity (%) Overall Accuracy (%) 
Death 6 14 30.0 91.7 63.6 Alive 2 22 
 
The Cox model was used for stratifying all the 73 patient samples in Ried et al data into low-risk and 
high-risk groups based on the 5-gene signature. Out of the 73 patients, a total of 37 patients had no 
recurrence with survival times less than 5 years. Twenty-nine patients had overall survival times less than 
5 years without any event (death). The relapse outcome for the 37 patients and the overall survival 
outcome for the 29 patients is currently unknown. Table 4.32 shows the prospective prognostic 





respectively. The follow-up information for these patients is being collected. When it becomes available 

























Number Patient ID 
Predicted group by 
Cox model (RFS)          Patient ID 
Predicted group by 
Cox model (OS) 
1 CC-P1 Low Risk CC-P1 Low Risk 
2 CC-P2 High Risk CC-P4 Low Risk 
3 CC-P4 Low Risk CC-P7 Low Risk 
4 CC-P7 Low Risk CC-P8 Low Risk 
5 CC-P8 High Risk CC-P9 Low Risk 
6 CC-P10 Low Risk CC-P11 High Risk 
7 CC-P13 Low Risk CC-P13 Low Risk 
8 CC-P18 High Risk CC-P16 Low Risk 
9 CC-P20 High Risk CC-P18 Low Risk 
10 CC-P21 Low Risk CC-P20 Low Risk 
11 CC-P22 High Risk CC-P21 Low Risk 
12 CC-P23 Low Risk CC-P22 High Risk 
13 CC-P25 Low Risk CC-P25 Low Risk 
14 CC-P28 High Risk CC-P28 High Risk 
15 CC-P29 High Risk CC-P31 Low Risk 
16 CC-P31 Low Risk CC-P35 Low Risk 
17 CC-P34 High Risk CC-P36 Low Risk 
18 CC-P35 High Risk CC-P37 Low Risk 
19 CC-P37 Low Risk CC-P38 Low Risk 
20 CC-P38 Low Risk CC-P40 Low Risk 
21 CC-P40 Low Risk CC-P48 Low Risk 
22 CC-P42 Low Risk CC-P50 Low Risk 
23 CC-P44 Low Risk CC-P51 Low Risk 
24 CC-P46 Low Risk CC-P60 Low Risk 
25 CC-P47 Low Risk CC-P62 Low Risk 
26 CC-P48 High Risk CC-P66 Low Risk 
27 CC-P50 Low Risk CC-P71 High Risk 
28 CC-P51 Low Risk CC-P72 Low Risk 
29 CC-P55 Low Risk CC-P73 Low Risk 
30 CC-P56 Low Risk   
31 CC-P60 Low Risk   
32 CC-P62 Low Risk   
33 CC-P66 Low Risk   
34 CC-P68 Low Risk   
35 CC-P70 High Risk   
36 CC-P71 High Risk   





4.5.5 Independence of 5-gene recurrence signature of tumor stage 
This part of the study was focused on verifying if the recurrence predictions obtained on Ried et al data 
were statistically significant when validated separately in Stage II and Stage III patients. It was seen that 
the 5-gene signature could stratify the patients into low-risk and high-risk groups in Stage II and Stage III 
samples individually with distinct relapse-free survival. The patient subgroups were obtained based on the 
Random Tree model. The patients belonging to the low-risk group had higher survival probabilities than 
those belonging to the high-risk group. Based on the predictions from Cox model using the 5-gene 
signature, Kaplan-Meier plots were plotted in Stage II and Stage III samples separately. But the patient 
stratification was not statistically significant and the results were not reported. So it can be said that 
Random Tree model is the best model for predicting recurrence using the 5-gene signature. These results 
confirm that the 5-gene recurrence signature might be applicable to prognostic categorization for the 
clinical management of colon cancer.  
                          
Figure 4.12 The 5-gene signature stratifies patients in Stage II tumors and Stage III tumors into 







4.5.6 External validation of the 5-gene signature on other colon cancer data 
This part of the study sought to explore the extent to which the 5-gene signature could be used for 
prediction of lymph node status, recurrence, and drug response in publicly available independent datasets. 
More than 50 classifiers available in Weka software were tested using a leave-one-out cross validation 
technique on each of the independent datasets to find a suitable classification scheme for validation. Due 
to the different number of attributes (matching genes), sample sizes and prediction variables one specific 
scheme could not be used for validation on all the datasets. Different classifiers had to be employed on 
the validation datasets to get fair prediction accuracy. As far as possible the same set of classifiers were 
presented in the comparison tables of validation datasets to provide a fair evaluation of the performance. 
The exact same set of classifiers could not be compared over all the validation datasets due to poor 
performances of classifiers on some datasets and good performances on other datasets. The following 
sections discuss the validation results and comparisons of various classifiers on the independent datasets 
in detail. 
4.5.6.1 Predicting lymph node status by leave-one-out cross validation on data from 
Koinuma et al. (n=17) PMID 16247484 
 
The data from Koinuma et al (Affymetrix HG U133 B platform) consisted of 20 patient samples of which 
3 patients were Duke’s stage D. The Duke’s stage D patients were not considered for validation. The 
search for matching genes with the 5-gene signature was done using the Affymetrix ids. There were 2 
matching genes (Table 4.33). The data used for validation consisted of the expression of these 2 genes in 
the 17 patient samples. Weka software was used for validation and lymph node status (positive/negative) 
was predicted. Different classification schemes including KStar, Random Tree, Threshold selector, 
Multilayer perceptron, and AD Tree were applied to this dataset to find the best scheme. Table 4.34 
shows the comparison between KStar and some of the classifiers used for validation on other datasets. 
KStar classifier performed better than the other classifiers. It had a sensitivity of 57.10%, a specificity of 





The difference in overall accuracy between KStar and other classifiers was not statistically significant due 
to the small sample size. 
Table 4.33 Matching genes in Koinuma et al data. 
GENE NAME  ID 
HSPA14-heat shock 70kDa protein 14 H200018991 
SLC25A5-solute carrier family 25 H200006643 
 
Table 4.34 Comparison of accuracies obtained from different classifiers for predicting lymph node 
status using the 5-gene signature. The improved overall accuracy of the prediction with the KStar 
classifier compared with other methods was assessed by significance testing (N = 17). 










KStar 57.10 70.00 63.55 64.70  
Random Tree 57.10 60.00 58.55 58.82 < 0.37 
Threshold selector 85.70 40.00 62.85 58.82 < 0.37 
Multilayer perceptron 28.60 50.00 39.30 41.17 < 0.09 
AD Tree 28.60 50.00 39.30 41.17 < 0.09 
 
Table 4.35 Confusion matrix obtained from the KStar classifier for predicting lymph node status 
using the 5-gene signature. 
Actual/Predicted a (positive) b (negative) 
a (positive) 4 3 
b (negative) 3 7 
 
4.5.6.2 Predicting recurrence by leave-one-out cross validation on data from Barrier et al. 
(n=18) PMID 16091735 
 
The data from Barrier et al (PMID 16091735) consisted of 22,283 genes and 18 patient samples. The 
search for matching genes with the 5-gene signature was done using the Affymetrix ids. There were 4 
matching genes (Table 4.36). The data used for validation consisted of the expression of these 4 genes in 
the 18 patients. Weka software was used for validation and recurrence (yes/no) was predicted. Different 
classification schemes including AD Tree, Random Tree, Threshold selector, KStar, and Multilayer 
perceptron were applied to this dataset to find the best scheme. Table 4.37 shows the comparison between 





better than the other classifiers. It had a sensitivity of 88.88%, a specificity of 88.88%, and an overall 
accuracy of 88.88%. Table 4.38 shows the confusion matrix for AD Tree classifier. The difference in 
overall accuracy between AD Tree and other classifiers was not statistically significant due to the small 
sample size. 
Table 4.36 Matching genes in Barrier et al data. 
GENE NAME  ID 
TPD52L2-tumor protein D52-like2 H200013992 
ZNF187-zinc finger protein 187 (ZNF187) H200015602 
HSPA14-heat shock 70kDa protein 14 H200018991 
SLC25A5-solute carrier family 25 H200006643 
 
Table 4.37 Comparison of accuracies obtained from different classifiers for predicting recurrence 
using the 5-gene signature. The improved overall accuracy of the prediction with the AD Tree 
classifier compared with other methods was assessed by significance testing (N = 18). 










AD Tree 88.88 88.88 88.88 88.88  
Random Tree 66.66 66.66 66.66 66.66 < 0.06 
Threshold selector 77.80 66.70 72.25 72.22 < 0.10 
KStar 77.80 55.60 66.70 66.66 < 0.06 
Multilayer perceptron 77.80 77.80 77.80 77.77 < 0.18 
 
Table 4.38 Confusion matrix obtained from the AD Tree classifier for predicting recurrence using 
the 5-gene signature. 
Actual/Predicted a (recurrence) b (no recurrence) 
a (recurrence) 8 1 
b (no recurrence) 1 8 
 
 
4.5.6.3 Predicting recurrence by leave-one-out cross validation on data from Barrier et al. 
(n=50) (PMID 16966692) 
 
The data from Barrier et al (PMID 16966692) consisted of 22,283 genes and 50 patient samples. The 
search for matching genes with the 5-gene signature was done using the Affymetrix ids. There were 4 





the 50 patient samples. Weka software was used for validation and recurrence (yes/no) was predicted. 
Different classification schemes including Threshold selector, KStar, IB1, AD Tree, and Multilayer 
perceptron were applied to this dataset to find the best scheme. Table 4.40 shows the comparison between 
Threshold selector and some of the classifiers used for validation on other datasets. Threshold selector 
classifier performed better than the other classifiers. It had a sensitivity of 84.00%, a specificity of 
68.00%, and an overall accuracy of 76.00%. Table 4.41 shows the confusion matrix for Threshold 
selector classifier. The difference in overall accuracy between Threshold selector and other classifiers was 
not statistically significant due to the small sample size. 
Table 4.39 Matching genes in Barrier et al data. 
GENE NAME  ID 
TPD52L2-tumor protein D52-like2 H200013992 
ZNF187-zinc finger protein 187 (ZNF187) H200015602 
HSPA14-heat shock 70kDa protein 14 H200018991 
SLC25A5-solute carrier family 25 H200006643 
 
Table 4.40 Comparison of accuracies obtained from different classifiers for predicting recurrence 
using the 5-gene signature. The improved overall accuracy of the prediction with the Threshold 
selector classifier compared with other methods was assessed by significance testing (N = 50). 










Threshold selector 84.00 68.00 76.00 76.00  
KStar 80.00 68.00 74.00 74.00 < 0.40 
IB1 76.00 72.00 74.00 74.00 < 0.40 
AD Tree 76.00 64.00 70.00 70.00 < 0.24 
Multilayer perceptron 60.00 68.00 64.00 64.00 < 0.09 
 
Table 4.41 Confusion matrix obtained from the Threshold selector classifier for predicting 
recurrence using the 5-gene signature. 
Actual/Predicted a (no recurrence) b (recurrence) 
a (no recurrence) 17 8 






4.5.6.4 Predicting recurrence by leave-one-out cross validation on data from Barrier et al. 
(n=24) (PMID 17043639) 
 
The data from Barrier et al (PMID 17043639) consisted of 22,283 genes and 24 patient samples. The 
search for matching genes was done using the Affymetrix ids. There were 4 matching genes (Table 4.42). 
The data used for validation consisted of the expression of these 4 genes in the 24 patient samples. Weka 
software was used for validation and recurrence (yes/no) was predicted. Different classification schemes 
including Threshold selector, Logistic regression, LWL, Multilayer perceptron, and AD Tree were 
applied to this dataset to find the best scheme. Table 4.43 shows the comparison between Threshold 
selector and some of the classifiers used for validation on other datasets. Threshold selector classifier 
performed better than the other classifiers. It had a sensitivity of 50.00%, a specificity of 92.90%, and an 
overall accuracy of 75.00%. Table 4.44 shows the confusion matrix for Threshold selector classifier. The 
difference in overall accuracy between Threshold selector and other classifiers was not statistically 
significant due to the small sample size. 
Table 4.42 Matching genes in Barrier et al data. 
GENE NAME  ID 
TPD52L2-tumor protein D52-like2  H200013992 
ZNF187-zinc finger protein 187 (ZNF187) H200015602 
HSPA14-heat shock 70kDa protein 14 H200018991 
SLC25A5-solute carrier family 25 H200006643 
 
Table 4.43 Comparison of accuracies obtained from different classifiers for predicting recurrence 
using the 5-gene signature. The improved overall accuracy of the prediction with the Threshold 
selector classifier compared with other methods was assessed by significance testing (N = 24). 










Threshold selector 50.00 92.90 47.63 75.00  
Logistic regression 60.00 78.60 69.30 70.83 < 0.38 
LWL 70.00 71.40 70.70 70.83 < 0.38 
Multilayer perceptron 60.00 78.60 69.30 70.83 < 0.38 






Table 4.44 Confusion matrix obtained from the Threshold selector classifier for predicting 
recurrence using the 5-gene signature. 
Actual/Predicted a (no recurrence) b (recurrence) 
a (no recurrence) 13 1 
b (recurrence) 5 5 
 
4.5.6.5 Predicting the response of cell lines in NCI-60 (U133A GCRMA) data (n=34) by 
leave-one-out cross validation 
 
This dataset34
Table 4.45 Matching genes in NCI-60 U133A data. 
 consisted of 21,225 genes and 60 cell lines (41). Our focus was on the sensitive and 
resistant cell lines, so cell lines with intermediate response were not considered for validation. A total of 
34 cell lines (17 sensitive and the other 17 resistant to the drug 5-FU) were used in validation. The search 
for matching genes was done using the gene symbols. There were 4 matching genes (Table 4.45). The 
data used for validation consisted of the expression of these 4 genes in the 34 cell lines. Weka software 
was used for validation and the response (sensitive/resistant) for the drug 5-FU (fluorouracil) was 
predicted. Different classification schemes including Threshold selector, Multilayer perceptron, Random 
Tree, KStar, and AD Tree were applied to this dataset to find the best scheme. Table 4.46 shows the 
comparison between Threshold selector and some of the classifiers used for validation on other datasets. 
Threshold selector classifier performed better than the other classifiers. It had a sensitivity of 82.40%, a 
specificity of 64.70%, and an overall accuracy of 73.52%. Table 4.47 shows the confusion matrix for 
Threshold selector classifier. The difference in overall accuracy between Threshold selector and 
Multilayer perceptron (p < 0.01), KStar (p < 0.04), AD Tree (p < 0.02) was statistically significant. 
GENE NAME  ID 
TPD52L2-tumor protein D52-like2 H200013992 
ZNF187-zinc finger protein 187 (ZNF187) H200015602 
HSPA14-heat shock 70kDa protein 14 H200018991 
SLC25A5-solute carrier family 25 H200006643 
 
 






Table 4.46 Comparison of accuracies obtained from different classifiers for predicting drug 
response using the 5-gene signature. The improved overall accuracy of the prediction with the 
Threshold selector classifier compared with other methods was assessed by significance testing (N = 
34). 










Threshold selector 82.40 64.70 73.55 73.52  
Multilayer perceptron 52.90 35.30 44.10 44.11 < 0.01 
Random Tree 58.80 52.90 55.85 55.88 < 0.07 
KStar 64.70 41.20 52.95 52.94 < 0.04 
AD Tree 41.20 52.90 47.05 47.05 < 0.02 
 
Table 4.47 Confusion matrix obtained from the Threshold selector classifier for predicting drug 
response using the 5-gene signature. 
Actual/Predicted a (sensitive) b (resistant) 
a (sensitive) 14 3 
b (resistant) 6 11 
 
4.5.6.6 Predicting the response of cell lines in NCI-60 (U133B GCRMA) data (n=34) by 
leave-one-out cross validation 
 
This dataset35
                                                     
35 http://discover.nci.nih.gov/cellminer/loadDownload.do 
 consisted of 17910 genes and 60 cell lines (41). Our focus was on the sensitive and resistant 
cell lines, so cell lines with intermediate response were not considered for validation. A total of 34 cell 
lines (17 sensitive and the other 17 resistant to the drug 5-FU) were used in validation. The search for 
matching genes was done using the gene symbols. There was 1 matching gene (Table 4.48). The data 
used for validation consisted of the expression of this gene in the 34 cell lines. Weka software was used 
for validation and the response (sensitive/resistant) for the drug 5-FU (fluorouracil) was predicted. 
Different classification schemes including Threshold selector, AD Tree, Random Tree, IB1, and KStar 
were applied to this dataset to find the best scheme. Table 4.49 shows the comparison between Threshold 
selector and some of the classifiers used for validation on other datasets. Threshold selector classifier 





overall accuracy of 82.35%. Table 4.50 shows the confusion matrix for Threshold selector classifier. The 
difference in overall accuracy between Threshold selector and AD Tree (p < 0.05), Random Tree (p < 
0.01), IB1 (p < 0.05), KStar (p < 0.01) was statistically significant. 
Table 4.48 Matching genes in NCI-60 U133B data. 
GENE NAME  ID 
HSPA14-heat shock 70kDa protein 14 H200018991 
 
Table 4.49 Comparison of accuracies obtained from different classifiers for predicting drug 
response using the 5-gene signature. The improved overall accuracy of the prediction with the 
Threshold selector classifier compared with other methods was assessed by significance testing (N = 
34). 










Threshold selector 82.35 82.35 82.35 82.35  
AD Tree 64.70 64.70 64.70 64.70 < 0.05 
Random Tree 52.90 58.80 55.85 55.88 < 0.01 
IB1 52.90 47.10 50.00 50.00 < 0.01 
KStar 58.80 29.40 44.10 44.11 < 0.01 
 
Table 4.50 Confusion matrix obtained from the Threshold selector classifier for predicting drug 
response using the 5-gene signature. 
Actual/Predicted a (sensitive) b (resistant) 
a (sensitive) 14 3 











4.5.7 Summary of validation results of 5-gene signature 
Table 4.51 shows the details of different validation datasets, predicted variables, classifiers used and 
different accuracies obtained using the 5-gene signature. For each dataset the classifier with the highest 
overall accuracy was reported.  
Table 4.51 Summary of validation results of 3-gene signature on Ried et al data, independent colon 
cancer datasets and NCI 60 data. 















Tree Recurrence 70.00 88.46 79.23 83.33 




model Recurrence 70.00 80.80 75.40 77.80 
Koinuma et al 
(n=17) 
PMID 16247484 
KStar Lymph node status 57.10 70.00 63.55 64.70 
Barrier et al 
(n=18) 
PMID 16091735 
AD Tree Recurrence 88.88 88.88 88.88 88.88 




selector Recurrence 84.00 68.00 76.00 76.00 




selector Recurrence 50.00 92.90 47.63 75.00 







82.40 64.70 73.55 73.52 















4.6 Comparison of 3-gene and 5-gene signatures 
This part of the study discusses the 3-gene and 5-gene recurrence signatures and compares them. The 
gene SLC25A5 was common in both the gene signatures. Based on the prediction accuracies obtained 
from the independent validation datasets, it can be seen that the 3-gene signature performs better than the 
5-gene signature. But the patient stratification in Stage II and Stage II tumor samples, by both the gene 
signatures were statistically significant. It can be concluded that both the 3-gene and 5-gene signatures 
could be used to predict recurrence and identify patients at high-risk of recurrence. Table 4.52 shows the 
comparison between 3-gene signature and 5-gene signature in detail. The difference in the prediction 
accuracies obtained from 3-gene and 5-gene signature on NCI-60 U133A data was statistically 
significant, whereas the results on other datasets were not significant. 
Table 4.52 Comparison of prediction accuracies obtained from 3-gene and 5-gene signatures on 
independent datasets. The improved overall accuracy of the prediction with the 3-gene signature 
compared with the 5-gene signature was assessed by significance testing. 
Dataset 









et al data 
(n=17) 
Barrier 
et al data 
(n=18) 
Barrier 











variable Recurrence Recurrence 
Lymph 





















(%) 80.00 80.00 71.40 88.90 76.00 94.10 88.23 
Specificity 





















(%) 70.00 70.00 57.10 88.88 84.00 82.40 82.35 
Specificity 




83.33 77.80 64.70 88.88 76.00 73.52 82.35 






In this chapter, we described how the recurrence gene signatures were identified. A combinatorial scheme 
was utilized for feature selection. Firstly, variable selection using random forests was applied on the 
preprocessed data to identify gene subsets, and secondly, InfoGain attribute selection technique was 
applied to reduce the dimensionality of the gene signatures without decreasing the predictive power. Two 
prediction models were built independently with the 3-gene and the 5-gene signatures using classifiers in 
Weka software to predict the risk stage of the patients in the testing set (patients whose recurrence status 
is currently unknown). The subgroups of patients without recurrence and survival time more than 5 years, 
and the patients having recurrence within 5 years after surgery obtained from the Cox model had a 
sensitivity of 80.0% and a specificity of 96.1%, using the 3-gene signature. Using the 5-gene signature, 
the sensitivity was 70.0% and the specificity was 80.8%. The Kaplan-Meier plots for the 3-gene signature 
and the 5-gene signature on Ried et al data obtained based on the Cox model stratified patients into 
distinct low-risk and high-risk groups. Both the gene signatures were cross validated on independent 
colon cancer data sets. The drug response of 5-FU (fluorouracil) on the NCI-60 cell line data was 
predicted. To confirm the prognostic applicability of the recurrence gene signatures, Kaplan Meier curves 
were plotted separately for Stage II and Stage III patients based on the predicted subgroups. The 
stratification was statistically significant (log-rank tests, p<0.05) for the 3-gene and 5-gene signatures. 
This confirms that it is feasible to predict recurrence in the Stage II and Stage III tumors with the 3-gene 










Validation of the identified gene signatures on rectal cancer data 
5.1 Introduction 
As colon cancer and rectal cancer are anatomically related, this part of the study sought to explore 
whether the identified colon cancer gene signatures could predict lymph node metastasis and generate 
significant patient stratification into low-risk and high-risk groups on rectal cancer data. The rectal cancer 
data was obtained from Ried et al (n=29) (PMID 16397240) (32). The 29 patients included in this study 
were all participants in a multicenter, randomized prospective phase III clinical trial treated at the 
Department of General Surgery, University Medical Center Gottingen, Germany. This data set of 29 
carcinomas and 20 mucosa biopsies includes 12 patient-matched pairs of biopsies from tumor and normal 
mucosa. The lymph node status, chemoradiotherapy response, disease-free survival, and overall survival 
information was available for all the patients. All the patients received a dose of 50.4Gy of radiation 
accompanied by FU (Fluorouracil). The following sections describe the validation results of the 9-gene 
lymph node status signature, 3-gene and 5-gene recurrence signatures on rectal cancer data including 
time-dependent ROC and Kaplan-Meier analyses. 
5.2 Validation results of the 9-gene signature on rectal cancer data 
5.2.1 Predicting lymph node status by leave-one-out cross validation on cDNA 1 files 
 
The cDNA 1 data files from Ried et al (PMID 16397240) consisted of 23 patient samples. The search for 
matching genes was done using the gene symbols. There were 3 matching genes (Table 5.1). The data 
used for validation consisted of the expression of these 3 genes in the 23 patient samples. Weka software 
was used for validation and lymph node status (negative/positive) was predicted. Different classification 
schemes including AdaboostM1, Multiboost AB, Random Tree, IB1, and Multilayer perceptron were 





some of the classifiers used for validation on other datasets. AdaboostM1 classifier performed better than 
the other classifiers. It had a sensitivity of 87.50%, a specificity of 57.10%, and an overall accuracy of 
78.26%. Table 5.3 shows the confusion matrix for AdaboostM1 classifier. The difference in overall 
accuracy between AdaboostM1 and other classifiers was not statistically significant. 
Table 5.1 Matching genes in Ried et al rectal cancer data. 
GENE NAME  ID 
SNRPD3-small nuclear  ribonucleoprotein H200000411 
PLXNB2-plexin B2, mRNA H200000861 
ITGB1-integrin,beta1 (fibronectin) H200021334 
 
Table 5.2 Comparison of accuracies obtained from different classifiers for predicting lymph node 
status using the 9-gene signature. The improved overall accuracy of the prediction with the 
AdaboostM1 classifier compared with other methods was assessed by significance testing (N = 23). 










AdaboostM1 87.50 57.10 72.30 78.26  
Multiboost AB 81.30 28.60 54.95 65.21 <0.17 
Random Tree 81.30 28.60 54.95 65.21 <0.17 
IB1 87.50 42.90 65.20 73.91 <0.35 
Multilayer perceptron 81.30 28.60 54.95 65.21 <0.17 
 
Table 5.3 Confusion matrix obtained from the AdaboostM1 classifier for predicting lymph node 
status using the 9-gene signature. 
Actual/Predicted a (node negative) b (node positive) 
a (node negative) 4 3 
b (node positive) 2 14 
 
5.2.2 Predicting lymph node status by leave-one-out cross validation on cDNA2 files 
 
The cDNA 2 data files from Ried et al (PMID 16397240) consisted of 23 patient samples. The search for 
matching genes was done using the gene symbols. There were 3 matching genes (Table 5.4). The data 
used for validation consisted of the expression of these 3 genes in the 23 patient samples. Weka software 





schemes including AdaboostM1, Multiboost AB, Random Tree, IB1, and JRip were applied to this dataset 
to find the best scheme. Table 5.5 shows the comparison between AdaboostM1 and some of the classifiers 
used for validation on other datasets. AdaboostM1 classifier performed better than the other classifiers. It 
had a sensitivity of 93.80%, a specificity of 42.90%, and an overall accuracy of 78.26%. Table 5.6 shows 
the confusion matrix for AdaboostM1 classifier. The difference in overall accuracy between AdaboostM1 
and other classifiers was not statistically significant due to the small sample size. 
Table 5.4 Matching genes in Ried et al rectal cancer data. 
GENE NAME  ID 
SNRPD3-small nuclear  ribonucleoprotein H200000411 
PLXNB2-plexin B2, mRNA H200000861 
ITGB1-integrin,beta1 (fibronectin) H200021334 
 
Table 5.5 Comparison of accuracies obtained from different classifiers for predicting lymph node 
status using the 9-gene signature. The improved overall accuracy of the prediction with the 
AdaboostM1 classifier compared with other methods was assessed by significance testing (N = 23). 










AdaboostM1 93.80 42.90 68.35 78.26  
Multiboost AB 75.00 14.30 44.65 56.52 <0.06 
Random Tree 68.80 28.60 48.70 56.52 <0.06 
IB1 68.80 42.90 55.85 60.86 <0.11 
JRip 93.80 28.60 61.20 73.91 <0.37 
 
Table 5.6 Confusion matrix obtained from the AdaboostM1 classifier for predicting lymph node 
status using the 9-gene signature. 
Actual/Predicted a (node negative) b (node positive) 
a (node negative) 3 4 
b (node positive) 1 15 
 
5.2.3 Predicting lymph node status by leave-one-out cross validation on tumor 
biopsies 1 files 
 
The tumor biopsies 1 data files from Ried et al (PMID 16397240) consisted of 17 patient samples. The 





The data used for validation consisted of the expression of these 9 genes in the 17 patient samples. Weka 
software was used for validation and lymph node status (negative/positive) was predicted. Different 
classification schemes including Decision stump, Multilayer perceptron, Random Tree, AdaboostM1, and 
IB1 were applied to this dataset to find the best scheme. Table 5.8 shows the comparison between 
Decision stump and some of the classifiers used for validation on other datasets. Decision stump classifier 
performed better than the other classifiers. It had a sensitivity of 75.00%, a specificity of 80.00%, and an 
overall accuracy of 76.47%. Table 5.9 shows the confusion matrix for Decision stump classifier. The 
difference in overall accuracy between Decision stump and Multilayer perceptron (p < 0.04), Random 
Tree (p < 0.04) was statistically significant. 
Table 5.7 Matching genes in Ried et al rectal cancer data. 
GENE NAME  ID 
SNRPD3-small nuclear  ribonucleoprotein H200000411 
IFRG28-28kD interferon responsive pro H200004627 
PLXNB2-plexin B2, mRNA H200000861 
DC50-hypothetical protein DC50 H200019106 
FLJ11078-hypothetical protein FLJ1107 H200016227 
MGC16044-hypothetical protein MGC1604 H200020589 
RNF6-ring finger protein (C3H2C3 type) H200004174 
POU6F2-POU domain, class 6,transcript H200015474 
ITGB1-integrin,beta1 (fibronectin)  H200021334 
 
Table 5.8 Comparison of accuracies obtained from different classifiers for predicting lymph node 
status using the 9-gene signature. The improved overall accuracy of the prediction with the 
Decision stump classifier compared with other methods was assessed by significance testing (N = 
17). 










Decision stump 75.00 80.00 77.50 76.47  
Multilayer perceptron 58.30 20.00 39.15 47.05 <0.04 
Random Tree 58.30 20.00 39.15 47.05 <0.04 
AdaboostM1 66.70 20.00 43.33 52.94 <0.08 







Table 5.9 Confusion matrix obtained from the Decision stump classifier for predicting lymph node 
status using the 9-gene signature. 
Actual/Predicted a (node positive) b (node negative) 
a (node positive) 9 3 
b (node negative) 1 4 
 
5.2.4 Predicting lymph node status by leave-one-out cross validation on tumor 
biopsies 2 files 
 
The tumor biopsies 2 data files from Ried et al (PMID 16397240) consisted of 17 patient samples. The 
search for matching genes was done using the gene symbols. There were 9 matching genes (Table 5.10). 
The data used for validation consisted of the expression of these 9 genes in the 17 patient samples. Weka 
software was used for validation and lymph node status (negative/positive) was predicted. Different 
classification schemes including J48, Random Tree, Adaboost M1, Multiboost AB, and Multilayer 
perceptron were applied to this dataset to find the best scheme. Table 5.11 shows the comparison between 
J48 and some of the classifiers used for validation on other datasets. J48 classifier performed better than 
the other classifiers. It had a sensitivity of 75.00%, a specificity of 60.00%, and an overall accuracy of 
70.58%. Table 5.12 shows the confusion matrix for J48 classifier. The difference in overall accuracy 
between J48 and other classifiers was not statistically significant due to the small sample size. 
Table 5.10 Matching genes in Ried et al rectal cancer data. 
GENE NAME  ID 
SNRPD3-small nuclear  ribonucleoprotein H200000411 
IFRG28-28kD interferon responsive pro H200004627 
PLXNB2-plexin B2, mRNA H200000861 
DC50-hypothetical protein DC50 H200019106 
FLJ11078-hypothetical protein FLJ1107 H200016227 
MGC16044-hypothetical protein MGC1604 H200020589 
RNF6-ring finger protein (C3H2C3 type) H200004174 
POU6F2-POU domain, class 6,transcript H200015474 







Table 5.11 Comparison of accuracies obtained from different classifiers for predicting lymph node 
status using the 9-gene signature. The improved overall accuracy of the prediction with the J48 
classifier compared with other methods was assessed by significance testing (N = 17). 










J48 75.00 60.00 67.50 70.58  
Random Tree 75.00 40.00 57.50 64.70 <0.36 
Adaboost M1 66.70 40.00 53.35 58.82 <0.24 
Multiboost AB 75.00 20.00 47.50 58.82 <0.24 
Multilayer perceptron 66.70 40.00 53.35 58.82 <0.24 
 
Table 5.12 Confusion matrix obtained from the J48 classifier for predicting lymph node status 
using the 9-gene signature. 
Actual/Predicted a (node positive) b (node negative) 
a (node positive) 9 3 
b (node negative) 2 3 
 
5.2.5 Predicting chemoradiotherapy response by leave-one-out cross validation on 
cDNA 1 files 
 
The cDNA 1 data files from Ried et al (PMID 16397240) consisted of 23 patient samples. The search for 
matching genes was done using the gene symbols. There were 3 matching genes (Table 5.13). The data 
used for validation consisted of the expression of these 3 genes in the 23 patient samples. Weka software 
was used for validation and chemoradiotherapy response (yes/no) was predicted. Different classification 
schemes including JRip, J48, AdaboostM1, Random Tree, and Multilayer perceptron were applied to this 
dataset to find the best scheme. Table 5.14 shows the comparison between JRip and some of the 
classifiers used for validation on other datasets. JRip classifier performed better than the other classifiers. 
It had a sensitivity of 55.60%, a specificity of 85.70%, and an overall accuracy of 73.91%. Table 5.15 
shows the confusion matrix for JRip classifier. The difference in overall accuracy between JRip and J48 







Table 5.13 Matching genes in Ried et al rectal cancer data. 
GENE NAME  ID 
SNRPD3-small nuclear  ribonucleoprotein H200000411 
PLXNB2-plexin B2, mRNA H200000861 
ITGB1-integrin,beta1 (fibronectin)  H200021334 
 
Table 5.14 Comparison of accuracies obtained from different classifiers for predicting 
chemoradiotherapy response using the 9-gene signature. The improved overall accuracy of the 
prediction with the JRip classifier compared with other methods was assessed by significance 
testing (N = 23). 










JRip 55.60 85.70 70.65 73.91  
J48 33.30 57.10 45.20 47.82 <0.04 
AdaboostM1 44.40 78.60 61.50 65.21 <0.27 
Random Tree 44.40 71.40 57.90 60.86 <0.18 
Multilayer perceptron 55.60 64.30 59.95 60.86 <0.18 
 
Table 5.15 Confusion matrix obtained from the JRip classifier for predicting response using the 9-
gene signature. 
Actual/Predicted a (response) b (no response) 
a (response) 5 4 
b (no response) 2 12 
 
 
5.2.6 Predicting chemoradiotherapy response by leave-one-out cross validation on 
cDNA2 files 
 
The cDNA 2 data files from Ried et al (PMID 16397240) consisted of 23 patient samples. The search for 
matching genes was done using the gene symbols. There were 3 matching genes (Table 5.16). The data 
used for validation consisted of the expression of these 3 genes in the 23 patient samples. Weka software 
was used for validation and chemoradiotherapy response (yes/no) was predicted. Different classification 
schemes including JRip, AdaboostM1, IB1, AD Tree, and Multiboost AB were applied to this dataset to 
find the best scheme. Table 5.17 shows the comparison between JRip and some of the classifiers used for 
validation on other datasets. JRip classifier performed better than the other classifiers. It had a sensitivity 





matrix for JRip classifier. The difference in overall accuracy between JRip and other classifiers was not 
statistically significant due to the small sample size. 
Table 5.16 Matching genes in Ried et al rectal cancer data. 
GENE NAME  ID 
SNRPD3-small nuclear  ribonucleoprotein H200000411 
PLXNB2-plexin B2, mRNA H200000861 
ITGB1-integrin,beta1 (fibronectin)  H200021334 
 
Table 5.17 Comparison of accuracies obtained from different classifiers for predicting 
chemoradiotherapy response using the 9-gene signature. The improved overall accuracy of the 
prediction with the JRip classifier compared with other methods was assessed by significance 
testing (N = 23). 










JRip 77.80 85.70 81.75 82.60  
AdaboostM1 66.70 78.60 72.65 73.91 <0.24 
IB1 44.40 71.40 57.90 60.86 <0.06 
AD Tree 55.60 78.60 67.10 69.56 <0.15 
Multiboost AB 55.60 71.40 63.50 65.21 <0.10 
 
Table 5.18 Confusion matrix obtained from the JRip classifier for predicting response using the 9-
gene signature. 
Actual/Predicted a (response) b (no response) 
a (response) 7 2 
b (no response) 2 12 
 
 
5.2.7 Predicting chemoradiotherapy response by leave-one-out cross validation on 
tumor biopsies 1 files 
 
The tumor biopsies 1 data files from Ried et al (PMID 16397240) consisted of 17 patient samples. The 
search for matching genes was done using the gene symbols. There were 9 matching genes (Table 5.19). 
The data used for validation consisted of the expression of these 9 genes in the 17 patient samples. Weka 
software was used for validation and chemoradiotherapy response (yes/no) was predicted. Different 





KStar were applied to this dataset to find the best scheme. Table 5.20 shows the comparison between 
Random committee and some of the classifiers used for validation on other datasets. Random committee 
classifier performed better than the other classifiers. It had a sensitivity of 90.00%, a specificity of 
28.60%, and an overall accuracy of 64.70%. Table 5.21 shows the confusion matrix for Random 
committee classifier. The difference in overall accuracy between Random committee and other classifiers 
was not statistically significant due to the small sample size. 
Table 5.19 Matching genes in Ried et al rectal cancer data. 
GENE NAME  ID 
SNRPD3-small nuclear  ribonucleoprotein H200000411 
IFRG28-28kD interferon responsive pro H200004627 
PLXNB2-plexin B2, mRNA H200000861 
DC50-hypothetical protein DC50 H200019106 
FLJ11078-hypothetical protein FLJ1107 H200016227 
MGC16044-hypothetical protein MGC1604 H200020589 
RNF6-ring finger protein (C3H2C3 type) H200004174 
POU6F2-POU domain, class 6,transcript H200015474 
ITGB1-integrin,beta1 (fibronectin)  H200021334 
 
Table 5.20 Comparison of accuracies obtained from different classifiers for predicting 
chemoradiotherapy response using the 9-gene signature. The improved overall accuracy of the 
prediction with the Random committee classifier compared with other methods was assessed by 
significance testing (N = 17). 










Random committee 90.00 28.60 59.30 64.70  
Multiboost AB 80.00 14.30 47.15 52.94 <0.25 
IB1 70.00 42.90 56.45 58.82 <0.37 
Multilayer perceptron 50.00 28.60 39.30 41.17 <0.09 
KStar 70.00 42.90 56.45 58.82 <0.37 
 
Table 5.21 Confusion matrix obtained from the Random committee classifier for predicting 
response using the 9-gene signature. 
Actual/Predicted a (response) b (no response) 
a (response) 9 1 






5.2.8 Predicting chemoradiotherapy response by leave-one-out cross validation on 
tumor biopsies 2 files 
 
The tumor biopsies 2 data files from Ried et al (PMID 16397240) consisted of 17 patient samples. The 
search for matching genes was done using the gene symbols. There were 9 matching genes (Table 5.22). 
The data used for validation consisted of the expression of these 9 genes in the 17 patient samples. Weka 
software was used for validation and chemoradiotherapy response (yes/no) was predicted. Different 
classification schemes including Logistic regression, IB1, AdaboostM1, Multilayer perceptron, and 
Threshold selector were applied to this dataset to find the best scheme. Table 5.23 shows the comparison 
between Logistic regression and some of the classifiers used for validation on other datasets. Logistic 
regression classifier performed better than the other classifiers. It had a sensitivity of 80.00%, a specificity 
of 71.40%, and an overall accuracy of 76.47%. Table 5.24 shows the confusion matrix for Logistic 
regression classifier. The difference in overall accuracy between Logistic regression and AdaboostM1 (p 
< 0.04) was statistically significant. 
Table 5.22 Matching genes in Ried et al rectal cancer data. 
GENE NAME  ID 
SNRPD3-small nuclear  ribonucleoprotein H200000411 
IFRG28-28kD interferon responsive pro H200004627 
PLXNB2-plexin B2, mRNA H200000861 
DC50-hypothetical protein DC50 H200019106 
FLJ11078-hypothetical protein FLJ1107 H200016227 
MGC16044-hypothetical protein MGC1604 H200020589 
RNF6-ring finger protein (C3H2C3 type) H200004174 
POU6F2-POU domain, class 6,transcript H200015474 










Table 5.23 Comparison of accuracies obtained from different classifiers for predicting 
chemoradiotherapy response using the 9-gene signature. The improved overall accuracy of the 
prediction with the Logistic regression classifier compared with other methods was assessed by 
significance testing (N = 17). 










Logistic regression 80.00 71.40 75.70 76.47  
IB1 80.00 42.90 61.45 64.70 <0.23 
AdaboostM1 60.00 28.60 44.30 47.05 <0.04 
Multilayer perceptron 70.00 57.10 63.55 64.70 <0.23 
Threshold selector 40.00 85.70 62.85 58.82 <0.13 
 
Table 5.24 Confusion matrix obtained from the Logistic regression classifier for predicting 
response using the 9-gene signature. 
Actual/Predicted a (response) b (no response) 
a (response) 8 2 
b (no response) 2 5 
 
5.2.9 Time-dependent ROC analyses on rectal cancer data from Ried et al (n=23) 
using the 9-gene lymph node status signature 
 
To explore whether the 9-gene lymph node status signature could predict patient disease-free survival and 
overall survival, the survival and status information along with the expression data of the matching genes 
are used for getting the time-dependent ROC curves. There were 3 matching genes with the 9-gene 
signature. The expression data of these 3 genes in the 23 patient samples along with the survival 
information was used to plot the time-dependent ROC curves. The accuracy of 5-year disease-free 
survival prediction is 0.72 and 5-year overall survival prediction is 0.76, as represented by AUC for 
cDNA 1 data files. The accuracy of 5-year disease-free survival prediction is 0.79 and 5-year overall 





                            
 
Figure 5.1 Time-dependent ROC plots on rectal cancer data (n=23) for disease-free survival and 
overall survival using the 9-gene signature in cDNA1 data files. 
 
 
                           
 
Figure 5.2 Time-dependent ROC plots on rectal cancer data (n=23) for disease-free survival and 










5.2.10 Kaplan-Meier analyses on Ried et al rectal cancer data (n=23) using the 9-
gene lymph node status signature 
 
The cDNA 1 files in rectal cancer data were checked for matching genes with the 9-gene signature. There 
were 3 matching genes. The Cox model based on the expression of these 3 genes was used to get 
recurrence risk scores for the 23 patients. The choices for choosing a cut-off value for patient 
stratification are the peak value from histogram, mean risk score or median risk score. In this analysis, the 
median risk score was chosen as cut-off as it resulted in best patient stratification. Cut-off values of 0.41 
and 0.09 were chosen for relapse-free survival and overall survival in cDNA 1 files, respectively. The 
pamr package in R was used to plot the Kaplan-Meier curves. The low-risk and high-risk groups, had 
distinct relapse-free survival (p = 0.014, n=23, log-rank tests) and distinct overall survival (p = 0.043, 
n=23, log-rank tests), respectively for the data in cDNA1 files. Table 5.25 shows the different parameters 
obtained from the Cox model using the 9-gene signature for disease-free survival and overall survival in 
cDNA 1 data files. 
Table 5.25 Different parameters obtained from Cox model using the 9-gene signature for disease-
free survival and overall survival in cDNA 1 data files. 



















SNRPD3 -0.541 0.582 0.548 -0.987 0.32 0.476 1.61 0.84 0.567 0.57 
PLXNB2 1.955 7.070 1.363 1.435 0.15 1.335 3.80 1.91 0.699 0.48 






                           
 
Figure 5.3 Kaplan-Meier plots on rectal cancer data (n=23) for disease-free survival and overall 
survival using the 9-gene signature in cDNA 1 files. 
 
The cDNA 2 files in rectal cancer data were checked for matching genes with the 9-gene signature. There 
were 3 matching genes. The Cox model based on the expression of these 3 genes was used to get 
recurrence risk scores for the 23 patients. The choices for choosing a cut-off value for patient 
stratification are the peak value from histogram, mean risk score or median risk score. In this analysis, the 
median risk score was chosen as cut-off as it resulted in best patient stratification. Cut-off values 0.27 and 
-0.48 were chosen for relapse-free survival and overall survival in cDNA 2 files, respectively. The pamr 
package in R was used to plot the Kaplan-Meier curves. The low-risk and high-risk groups, had distinct 
relapse-free survival (p = 0.041, n=23, log-rank tests) and distinct overall survival (p = 0.0436, n=23, 
log-rank tests), respectively for the data in cDNA 2 files. Table 5.26 shows the different parameters 
obtained from the Cox model using the 9-gene signature for disease-free survival and overall survival in 







Table 5.26 Different parameters obtained from Cox model using the 9-gene signature for disease-
free survival and overall survival in cDNA 2 files. 



















SNRPD3 -0.122 0.885 0.671 -0.182 0.86 0.876 2.401 0.89 0.984 0.32 
PLXNB2 1.262 3.531 1.247 1.012 0.31 -0.973 0.378   2.11 -0.461 0.65 
ITGB1 -0.823 0.439 0.882 -0.933 0.35 -1.844 0.158 1.67 -1.104 0.27 
 
 
                         
 
Figure 5.4 Kaplan-Meier plots on rectal cancer data (n=23) for disease-free survival and overall 
survival using the 9-gene signature in cDNA 2 data files. 
 
5.2.11 Summary of validation results of 9-gene signature on rectal cancer data 
 
Table 5.27 shows the details of validation results on rectal cancer data in different groups of files. For 
each dataset the classifier with the highest overall accuracy was reported. The time-dependent ROC and 








Table 5.27 Summary of validation results of 9-gene signature on rectal cancer data. 
Rectal cancer 











cDNA1 files AdaboostM1 Lymph node status 87.50 57.10 72.30 78.26 




stump Lymph node status 75.00 80.00 77.50 76.47 
Tumor biopsies 
2 files J48 Lymph node status 75.00 60.00 67.50 70.58 
cDNA1 files JRip Chemoradiotherapy response 55.60 87.50 70.65 73.91 






response 90.00 28.60 59.30 64.70 
Tumor biopsies 
2 files Logistic 
Chemoradiotherapy 
response 80.00 71.40 75.70 76.47 
 
5.3 Validation results of the 3-gene signature on rectal cancer data 
5.3.1 Predicting lymph node status in tumor biopsies 2 files 
 
The tumor biopsies 2 data files from Ried et al (PMID 16397240) consisted of 17 patient samples. The 
search for matching genes was done using the gene symbols. There were 2 matching genes (Table 5.28). 
The data used for validation consisted of the expression of these 2 genes in the 17 patient samples. Weka 
software was used for validation and lymph node status (positive/negative) was predicted. Different 
classification schemes including KStar, Logistic regression, AD Tree, AdaboostM1, and Threshold 
selector were applied to this dataset to find the best scheme. Table 5.29 shows the comparison between 
KStar and some of the classifiers used for validation on other datasets. KStar classifier performed better 
than the other classifiers. It had a sensitivity of 83.33%, a specificity of 60.00%, and an overall accuracy 
of 76.47%. Table 5.30 shows the confusion matrix for KStar classifier. The difference in overall accuracy 






Table 5.28 Matching genes in Ried et al rectal cancer data. 
GENE NAME  ID 
E2F2-E2F transcription factor 2 (E2F2) H200012309 
SLC25A5-solute carrier family 25  H200006643 
 
Table 5.29 Comparison of accuracies obtained from different classifiers for predicting lymph node 
status using the 3-gene signature. The improved overall accuracy of the prediction with the KStar 
classifier compared with other methods was assessed by significance testing (N = 17). 










KStar 83.33 60.00 71.66 76.47  
Logistic regression 83.30 40.00 61.65 70.58 <0.35 
AD Tree 66.70 60.00 63.35 64.70 <0.23 
AdaboostM1 58.30 60.00 59.15 58.82 <0.14 
Threshold selector 41.70 80.00 60.85 52.94 <0.08 
 
Table 5.30 Confusion matrix obtained from the KStar classifier for predicting lymph node status 
using the 3-gene signature. 
Actual/Predicted a (node positive) b (node negative) 
a (node positive) 10 2 
b (node negative) 2 3 
 
5.3.2 Predicting chemoradiotherapy response in tumor biopsies 2 files 
 
The tumor biopsies 2 data files from Ried et al (PMID 16397240) consisted of 17 patient samples. The 
search for matching genes was done using the gene symbols. There were 2 matching genes (Table 5.31). 
The data used for validation consisted of the expression of these 2 genes in the 17 patient samples. Weka 
software was used for validation and chemoradiotherapy response (yes/no) was predicted. Different 
classification schemes including Decision stump, Multiboost AB, AdaboostM1, Logistic regression, and 
AD Tree were applied to this dataset to find the best scheme. Table 5.32 shows the comparison between 
Decision stump and some of the classifiers used for validation on other datasets. Decision stump classifier 
performed better than the other classifiers. It had a sensitivity of 90.00%, a specificity of 57.10%, and an 





difference in overall accuracy between Decision stump and AD Tree (p < 0.04) was statistically 
significant. 
Table 5.31 Matching genes in Ried et al rectal cancer data. 
GENE NAME  ID 
E2F2-E2F transcription factor 2 (E2F2) H200012309 
SLC25A5-solute carrier family 25  H200006643 
 
Table 5.32 Comparison of accuracies obtained from different classifiers for predicting 
chemoradiotherapy response using the 3-gene signature. The improved overall accuracy of the 
prediction with the Decision stump classifier compared with other methods was assessed by 
significance testing (N = 17). 










Decision stump 90.00 57.10 73.55 76.47  
Multiboost AB 90.00 28.60 59.30 64.70 <0.23 
AdaboostM1 70.00 42.90 56.45 58.82 <0.14 
Logisitc regression 70.00 28.60 49.30 52.94 <0.08 
AD Tree 50.00 42.90 46.45 47.05 <0.04 
 
Table 5.33 Confusion matrix obtained from the Decision stump classifier for predicting response 
using the 3-gene signature. 
Actual/Predicted a (response) b (no response) 
a (response) 9 1 
b (no response) 3 4 
 
5.3.3 Summary of validation results of 3-gene signature on rectal cancer data 
 
Table 5.34 shows the details of validation results of 3-gene signature on rectal cancer data in different 
groups of files. For each dataset the classifier with the highest overall accuracy was reported. The 
validation results on cDNA data files, time-dependent ROC and Kaplan-Meier analyses were not reported 







Table 5.34 Summary of validation results of 3-gene signature on rectal cancer data. 
Rectal cancer 

















response 90.00 57.10 73.55 76.47 
 
5.4 Validation results of the 5-gene signature on rectal cancer data 
5.4.1 Predicting lymph node status in tumor biopsies 2 files 
 
The tumor biopsies 2 data files from Ried et al (PMID 16397240) consisted of 17 patient samples. The 
search for matching genes was done using the gene symbols. There were 2 matching gene (Table 5.35). 
The data used for validation consisted of the expression of these 2 genes in the 17 patient samples. Weka 
software was used for validation and lymph node status (positive/negative) was predicted. Different 
classification schemes including Multiboost AB, Logitboost, Random Tree, Multilayer perceptron, and 
LWL were applied to this dataset to find the best scheme. Table 5.36 shows the comparison between 
Multiboost AB and some of the classifiers used for validation on other datasets. Multiboost AB classifier 
performed better than the other classifiers. It had a sensitivity of 83.30%, a specificity of 40.00%, and an 
overall accuracy of 70.58%. Table 5.37 shows the confusion matrix for Multiboost AB classifier. The 
difference in overall accuracy between Multiboost AB and other classifiers was not statistically 
significant due to the small sample size. 
Table 5.35 Matching genes in Ried et al rectal cancer data. 
GENE NAME  ID 
TPD52L2-tumor protein D52-like2 H200013992 
ZNF187-zinc finger protein 187  H200015602 







Table 5.36 Comparison of accuracies obtained from different classifiers for predicting lymph node 
status using the 5-gene signature. The improved overall accuracy of the prediction with the 
Multiboost AB classifier compared with other methods was assessed by significance testing (N = 
17). 










Multiboost AB 83.30 40.00 61.65 70.58  
Adaboost M1 83.30 20.00 51.65 64.70 <0.36 
Random Tree 58.30 20.00 39.15 47.05 <0.09 
Random committee 75.00 20.00 47.50 58.82 <0.24 
LWL 75.00 20.00 47.50 58.82 <0.24 
 
Table 5.37 Confusion matrix obtained from the Multiboost AB classifier for predicting lymph node 
status using the 5-gene signature. 
Actual/Predicted a (node positive) b (node negative) 
a (node positive) 10 2 
b (node negative) 3 2 
 
5.4.2 Predicting chemoradiotherapy response in tumor biopsies 2 files 
 
The tumor biopsies 2 data files from Ried et al (PMID 16397240) consisted of 17 patient samples. The 
search for matching genes was done using the gene symbols. There were 3 matching genes (Table 5.38). 
The data used for validation consisted of the expression of these 3 genes in the 17 patient samples. Weka 
software was used for validation and chemoradiotherapy response (yes/no) was predicted. Different 
classification schemes including J48, AD Tree, IB1, Logistic regression, and AdaboostM1 were applied to 
this dataset to find the best scheme. Table 5.39 shows the comparison between J48 and some of the 
classifiers used for validation on other datasets. J48 classifier performed better than the other classifiers. 
It had a sensitivity of 90.00%, a specificity of 57.10%, and an overall accuracy of 76.47%. Table 5.40 
shows the confusion matrix for J48 classifier. The difference in overall accuracy between J48 and 






Table 5.38 Matching genes in Ried et al rectal cancer data. 
GENE NAME  ID 
TPD52L2-tumor protein D52-like2  H200013992 
ZNF187-zinc finger protein 187  H200015602 
SLC25A5-solute carrier family 25  H200006643 
 
Table 5.39 Comparison of accuracies obtained from different classifiers for predicting 
chemoradiotherapy response using the 5-gene signature. The improved overall accuracy of the 
prediction with the J48 classifier compared with other methods was assessed by significance testing 
(N = 17). 










J48 90.00 57.10 73.55 76.47  
AD Tree 80.00 42.90 61.45 64.70 <0.23 
IB1 50.00 57.10 53.55 52.94 <0.08 
Logistic regression 60.00 28.60 44.30 47.05 <0.04 
AdaboostM1 70.00 42.90 56.45 58.82 <0.14 
 
Table 5.40 Confusion matrix obtained from the J48 classifier for predicting response using the 5-
gene signature. 
Actual/Predicted a (response) b (no response) 
a (response) 9 1 
b (no response) 3 4 
 
5.4.3 Kaplan-Meier analyses on Ried et al rectal cancer data (n=23) using the 5-gene 
signature 
 
The cDNA 2 files in rectal cancer data were checked for matching genes with the 5-gene signature. There 
were 3 matching genes. The Cox model based on the expression of these 3 genes was used to get 
recurrence risk scores for the 23 patients. The choices for choosing a cut-off value for patient 
stratification are the peak value from histogram, mean risk score or median risk score. In this analysis, the 
median risk score was chosen as cut-off as it resulted in best patient stratification. Cut-off values of 0.17 
and -1.16 were chosen for relapse-free survival and overall survival, respectively. The pamr package in R 
was used to plot the Kaplan-Meier curves. The low-risk and high-risk groups, had distinct relapse-free 





respectively for the data in cDNA2 files. Table 5.41 shows the different parameters obtained from the 
Cox model using the 9-gene signature for disease-free survival and overall survival in cDNA 2 data files. 
Table 5.41 Different parameters obtained from Cox model using the 5-gene signature for relapse-
free survival and overall survival. 

















ZNF187 -0.2148 0.807 1.237 -0.1737 0.86 1.633 5.117 1.96 0.834 0.40 
SLC25A5 -0.0006 0.999 0.825 -0.0007 1.00 -0.604 0.547 1.52 -0.398 0.69 
 
                         
Figure 5.5 Kaplan-Meier plots on rectal cancer data (n=23) for disease-free survival and overall 
survival using the 5-gene signature in cDNA 2 data files. 
 
5.4.4 Summary of validation results of 5-gene signature on rectal cancer data 
Table 5.42 shows the details of validation results of 5-gene signature on rectal cancer data in different 
groups of files. For each dataset the classifier with the highest overall accuracy was reported. The time-
dependent ROC, Kaplan-Meier analyses and validation results on cDNA data files were not reported as 






Table 5.42 Summary of validation results of 5-gene signature on rectal cancer data. 
Rectal 


















J48 Chemoradiotherapy response 90.00 57.10 73.55 76.47 
 
5.5 Conclusion 
The 9-gene lymph node status signature on the whole had optimal prediction accuracy on the rectal cancer 
data set. The 9-gene signature might be used for predicting lymph node status and chemoradiotherapy 
response in rectal cancer data and to stratify patients into low-risk and high-risk groups. The 3-gene 
signature can be used to predict lymph node status and chemoradiotherapy response of the patients in 
tumor biopsies 2 data. The 5-gene signature can be used to stratify patients into low-risk and high-risk 















The advents of high throughput technologies, such as DNA microarrays are revolutionalizing the field of 
medicine. DNA microarrays are a powerful means of monitoring thousands of gene expression levels at 
the same time. Machine learning techniques are playing a pivotal role in analyzing the generated 
microarray data. Recent studies have successfully applied the machine learning approaches to predict the 
cancer stage, treatment outcome, drug response, and promise treatments tailored to the patients. Presently 
there are no gene tests available for clinical usage in colon cancer while there are gene tests like 
MammaPrint and Oncotype DX for breast cancer prognosis. Our study was focused in the direction of 
identifying important biomarkers to predict colon cancer stage and recurrence, building prognostic 
models, and stratifying patients into low-risk and high-risk groups based on cDNA microarray data. 
 In an effort to overcome the limitations of the traditional staging systems, in the first part of our 
study a 9-gene lymph node status signature was identified by feature selection using random forests and 
then discarding genes without differential expression. A prognostic patient stratification scheme was 
developed based on this 9-gene signature using the Cox model. In the second part of the study, we 
focused on identifying biomarkers predicting recurrence. This was achieved by a combinatorial scheme 
employing feature selection using random forests in the first step and then using InfoGain feature 
selection method in the next step. Two recurrence gene signatures were identified and patient 
stratification schemes were developed based on these signatures to identify subgroups of patients, at low 
and high-risks of recurrence. Recurrence prediction models were built using classifiers in Weka software 
based on these gene signatures. The gene signatures identified in this study could be used for classifying 
new colon cancer patients into different stages of the disease and different prognostic risk groups.  
 The analysis of microarray gene expression data through machine learning methods currently 
faces two major problems. Firstly the high dimensionality of the feature space and secondly the fact that 





for applications in domains, such as business, retail, and marketing. A typical data mining banking 
application, has thousands or millions of records, and at most a few hundred fields. In contrast, a 
microarray gene expression data may only have a few hundred records and thousands of fields. Also, 
majority of the techniques used in standard data mining applications are very sensitive to noise (1). We 
could solve the problem of high dimensionality to some extent by preprocessing the data and employing a 
combinatorial scheme for feature selection. In the future, there is a necessity for new machine learning 
techniques addressing the high dimensionality and noisy characteristics of microarray gene expression 
data. We faced with another problem of availability of colon cancer datasets. The number of colon cancer 
datasets publicly available is very less. They are not as widely available as lung cancer and breast cancer 
datasets. The colon cancer data used in our study was obtained from our research collaborator Dr.Ried. 
The survival information was not available for other colon cancer datasets used for validation and we 
could not perform the time-dependent ROC and Kaplan-Meier analyses. Availability of the survival 
information and more colon cancer datasets publicly in the future would allow for robust validation of the 
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